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ABSTRACT 
Epithelial ovarian carcinoma (EOC) is a heterogeneous disease generally classified into five 
histopathological subtypes; low- and high-grade serous, endometrioid, clear cell and 
mucinous carcinomas. Although each subtype has distinct clinical and molecular 
characteristics, they are all treated with surgery and platinum/ taxane chemotherapy. Despite 
initial responsiveness a majority of patients relapse into platinum-resistant and disseminated 
disease. This, together with often late diagnosis, makes EOC the most lethal gynecological 
cancer. Dissemination is mainly abdominal, via exfoliated tumor cells in peritoneal ascitic 
fluid. The origin and phenotype of cells in malignant ascites is poorly understood. Tumor 
progression of carcinomas towards metastasis includes epithelial-to-mesenchymal-transition 
(EMT), where epithelial cells gain a mesenchymal morphology to facilitate invasion. 
Progression and chemoresistance have also been attributed to a small population of highly 
tumorigenic and chemoresistant cancer stem cells, or tumor-initiating cells (TICs). In 
addition, altered cellular energetics is a hallmark of cancer wherefore tumor-specific 
metabolic features are potential targets for overcoming chemoresistance. 
In Paper I cell populations in malignant ascites were found to differ significantly with 
respect to protein expression levels of EMT and TIC markers. We identified two potential 
TIC profiles, highlighting a biological heterogeneity in ascitic tumor cell populations. The 
indicated presence of cancer-associated fibroblasts (CAFs) may further contribute to 
malignant properties. We found that CAF marker α-SMA expression was increased in 
clinical stage IV, compared to stage IIIC. 
Paper II reveals that long-term repeated cisplatin treatment can select for and/or induce a 
multiresistant cell population with EMT and TIC features. Resistance could be linked to 
upregulation of VDAC and HK-II, which form an anti-apoptotic complex on mitochondria. 
Multiresistant cells were sensitive to the lactate/ pyruvate analogue 3-BP that dissociates this 
complex, and particularly sensitive to 3-BP when combined with cisplatin in low doses. 
In Paper III expression of mitochondrial regulators PGC1α and TFAM was found to vary 
between EOC subtypes. For clear cell carcinomas (CCC) a profile consisting of low or 
undetectable levels of PGC1α, TFAM, ERα and low Ki-67 index was identified. This CCC 
profile, and also glycogen accumulation, was further linked to chemoresistance development 
in vitro. 
In Paper IV we used 1H NMR-based metabolomics to identify significant differences in the 
intracellular polar metabolome of parental and multiresistant EOC cell lines. Furthermore, we 
developed a tailored and reliable protocol for metabolic profiling of adherent cells, suitable 
for further characterization of metabolic alterations in EOC and other pathological conditions. 
Taken together, this thesis identifies signatures of progression and chemoresistance in EOC 
and highlights the need for subtype-specific treatment.  
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1 INTRODUCTION 
Most cells in the metazoan body carry a complete genome, to retain the ability to grow and 
divide during lifespan of the organism. Retained proliferation and programed cell death 
allows maintenance, including wound repair and replacement of cells, important for organism 
survival. Although tissue homeostasis is tightly regulated, various genetic and environmental 
mechanisms can alter the structure and content of the genome. As a result, mutated genes 
cause abnormal cell phenotypes, often with alterations in cellular growth programs, that give 
rise to large populations of cells, i.e. tumors, that no longer follow the rules for tissue 
homeostasis. Tumors can further be divided into two broad categories depending on their 
ability to invade nearby tissue; benign tumors that grow locally and do not invade, and 
malignant tumors that invade and cause metastatic tumors in distant organs. The majority of 
tumors arising in humans are benign and harmless to their host, except for rare cases where 
the tumor mass put pressure on vital organs. Some, but not all benign tumors, further 
develops into dysplasias with abnormal cells and major effects on the overall tissue 
architecture. Additional degrees of abnormality are found in neoplasias that can be pre-
malignant or malignant. Malignant neoplasias are collectively called cancer1, that caused 
approximately 8.2 million deaths worldwide in 2012 (Ferlay et al., 2014). 
Cancer is not one, but several diseases that can be broadly divided into subgroups based on 
the cellular origin of the tumor. The great majority of malignant tumors, carcinomas, arise in 
epithelial tissue. Non-epithelial cancers include sarcomas derived from mesenchymal cells in 
various connective tissues, hematopoietic malignancies2 in blood-forming tissues, and 
neuroectodermal tumors originating from cells in the central and peripheral nervous system. 
Irrespective of tumor origin, most malignant tumors acquire the same set of functional 
capabilities during tumor progression, i.e. the development from normal to malignant. These 
common characteristics, “the hallmarks of cancer”, includes the ability to; sustain 
proliferative signaling, evade growth suppressors, resist cell death, induce angiogenesis, 
enable replicative immortality and activate invasion and metastasis, avoid immune 
destruction and deregulate cellular energetics (Hanahan and Weinberg, 2000, 2011). In 
addition, two consequential characteristics of neoplasia, genomic instability and tumor-
promoting inflammation, assist acquisition of the other hallmarks (Hanahan and Weinberg, 
2011). Knowledge of the molecular mechanisms behind each hallmark leads to increased 
insights in tumor progression and makes it possible to identify new therapeutical targets.  
Although some types of cancer are curable, especially if detected in an early stage, a major 
clinical challenge is resistance to treatment. If treatment fails to kill all cancer cells, the 
remaining cell population can give rise to new, resistant tumors that eventually cause death of 
the patient. This is the case for ovarian carcinomas, where development of chemoresistance in 
                                                
1 Sometimes the term cancer is used more loosely to include all types of abnormal growth 
2 Includes leukemias with malignant cells that freely moves through the circulation as dispersed, single-cells 
instead of forming classical tumors. 
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addition to late-stage diagnosis make it the most lethal of gynecological cancer in the 
Western world (Lengyel, 2010). Unfortunately, the survival rates have improved very little in 
the last 30 years (Engel et al., 2002; Vaughan et al., 2011). Therefore, the work presented in 
this thesis aims to study tumor progression and chemoresistance in ovarian carcinomas, in 
order to provide insights of underlying molecular events that eventually can lead to 
development of new treatment strategies. 
 
 
Figure 1. The hallmarks of cancer. Overview of common characteristics of malignant neoplasias, including 
two emerging hallmarks, avoiding immune destruction and deregulating cellular energetics, and two enabling 
characteristics, genome instability and mutation and tumor-promoting inflammation. Adapted from Hanahan, D., 
Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. Cell 144, 646–674. Reprinted with permission 
from Elsevier. 
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1.1 EPITHELIAL OVARIAN CARCINOMA 
1.1.1 Epidemiology 
Epithelial ovarian carcinoma (EOC) is the seventh most common malignancy in women, with 
an incidence of 239 000 cases, causing 152 000 deaths worldwide in 2012 (Ferlay et al., 
2014). It affects women of all ages, although uncommon before age of 30, with a peak in 
incidence in women 65-74 years old. Incidence rates are highest in Northern Europe 
(Permuth-Wey and Sellers, 2009) with approximately 10 cases per 100 000 women in the 
Nordic countries (Engholm et al. NORDCAN database, version 6.1, 2014). The incidence in 
Sweden has been decreasing over the past decade and is now down to approximately 700 new 
cases per year3, mainly due to protective effects of oral contraception and reduced usage of 
hormone replacement in menopausal women (Collaborative Group on Epidemiological 
Studies of Ovarian Cancer et al., 2008; Mørch et al., 2009). The mortality has also decreased 
somewhat, but not at the same rate as the incidence (Figure 2). 
 
Figure 2. Ovarian cancer incidence and mortality. Incidence and mortality for ovarian cancer per 100 000 
women in Sweden 1980-2011. All ages are included, age-standardized rate according to world standard 
population. Source; NORDCAN database, available from http://www.ancr.nu, accessed on 14/10/2014.  
Approximately 90% of the malignant ovarian tumors are of epithelial origin but international 
statistics sometimes include rare cases of tumors arising in ovarian stroma or germ cells.  
In this thesis, the term EOC also includes tumor material from patients diagnosed with 
carcinomas originating from the fallopian tube or peritoneum, since these are prognostically 
and clinicopathologically indistinguishable from those originating from the ovary. 
  
                                                
3 Including patients diagnosed with fallopian tube carcinomas. 
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1.1.2 Pathogenesis and risk factors 
EOC tumors are classified into different subtypes based on morphological appearance 
according to WHO histopathological standards, including serous, endometrioid, clear cell, 
mucinous and undifferentiated tumors (International Agency for Research on Cancer and 
World Health Organization, 2014). Additional classification, based on molecular genetics, 
divides EOC into two broad categories designated types I and II (Vang et al., 2009; Kurman 
and Shih, 2011). Type I tumors, that are relatively stable genetically, include low-grade 
serous, low-grade endometrioid, clear cell and mucinous carcinomas. Type II consists of 
high-grade serous, high-grade endometrioid and undifferentiated/mixed tumors, all 
genetically highly unstable. 
In general, the use of oral contraceptives (Purdie et al., 2003), parity and breastfeeding (Hunn 
and Rodriguez, 2012) decrease the risk of developing any subtype of EOC, while the use of 
menopausal estrogen treatment increases the risk (Mørch et al., 2009). Genetic factors, like 
BRCA1 or BRCA2 mutations and Lynch-syndrome4 increase the risk (Gayther, 2012) and 
carriers are recommended prophylactic surgical removal of ovaries and fallopian tubes. Other 
risk factor are subtype specific and are further described for each subtype.  
The origin and pathogenesis of EOC have confused investigators for decades, although 
ovulation for long has been considered an important factor for EOC development. Ovulation 
causes damage to the ovarian surface and activates local tissue repair in a cyclic process that 
increase the risk for malignant transformation. A conventional theory suggests that malignant 
neoplasms originate from the ovarian surface epithelium (OSE) and/or cortical inclusion cysts 
(CICs), which are invaginations of epithelium in the ovarian stoma. However, recent studies 
strongly suggests that tumors develop in Müllerian duct-derived epithelia of the fallopian 
tube and endometrium and involve the ovary secondarily (Kurman and Shih, 2011).  
Serous tubal intraepithelial carcinomas (STICs) that closely resembles ovarian high-grade 
serous carcinomas were first described in women with a genetic predisposition to ovarian 
cancer (Piek et al., 2001). The model suggests that implantation of malignant cells from the 
fimbriated distal fallopian tube to the ovary give rise to high-grade serous tumors. 61% of 
pelvic high-grade serous carcinomas (including those of the ovary, fallopian tube and primary 
peritoneal) have been reported to involve STICs (Przybycin et al., 2010). Another possibility 
is that benign tubal epithelial cells implant on the, by ovulation disrupted, ovarian surface to 
form CICs (Kurman and Shih, 2010) that later progress to serous carcinomas. In addition, 
endometriotic lesions are precursors of the endometrioid and clear cell carcinomas (Nezhat et 
al., 2008). These lesions derives from the endometrium (lining of the uterus) that establish 
outside the uterine cavity as a result of retrograde menstruation, a condition known as 
endometriosis (Bulun, 2009).  
                                                
4 Genetic disorder with defects in DNA mismatch repair genes, which leads to microsatellite instability.  
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1.1.2.1 Serous carcinomas 
Serous carcinomas account for 75% of EOC (Köbel et al., 2010) and are further divided into 
low- and high-grade tumors, with distinct clinical and molecular features. Almost all serous 
tumors are high-grade serous carcinomas (HGSC), hence this is the most common EOC 
diagnosis.  
HGSC may arise in the fallopian tube epithelium, either directly from a carcinoma in the 
fallopian tube or from tubal epithelium implanted in the ovary forming a CICs (Nik et al., 
2014). Mutation in the TP53 gene as well as post-translational induced dysfunction of p53 is 
a hallmark for HGSC, found in close to all cases (Ahmed et al., 2010; Cancer Genome Atlas 
Research Network, 2011). Another common features in this subtype is BRCA pathway 
mutations, found in 51% cases in a cohort of 489 HGSC cases (Cancer Genome Atlas 
Research Network, 2011). This is in line with women carrying BRCA-mutations have 
increased risk to develop EOC, particular HGSC (Lakhani et al., 2004). Other signaling 
pathways that are altered are retinoblastoma (RB), phosphatidylinosidide 3-kinases 
(PI3K)/Akt and Notch (Cancer Genome Atlas Research Network, 2011). HGSC are thus a 
genetically heterogeneous disease with high chromosomal instability (Bowtell, 2010).  
Low-grade serous carcinomas (LGSC) represent 3-5% of all EOC cases (Köbel et al., 2010). 
TP53 mutations are uncommon and they have lower levels of chromosomal instability than 
HGSC (Vang et al., 2009; Lim and Oliva, 2013). Common mutations are those of KRAS, 
BRAF and ERBB2 oncogenes (Singer et al., 2003; Vang et al., 2009), all upstream of the 
mitogen-activated protein kinase (MAPK), resulting in activation of MAPK signaling and 
proliferation (Hsu et al., 2004). Two thirds of LGSC harbor these mutations that can also be 
found in serous borderline tumors, i.e. tumors with semi-malignant potential (Bonome et al., 
2005). They seem to share common molecular features and tumor specimens of LGSC often 
contain areas with borderline malignant potential (Malpica et al., 2004), suggesting that 
borderline serous tumors might transform into LGSC. Unlike in HGSC, a high body mass 
index (BMI) increases the risk of LGSC and serous borderline tumors (Olsen et al., 2013). 
1.1.2.2 Endometrioid carcinomas 
Approximately 10% of EOCs are endometrioid carcinomas (EC) (Köbel et al., 2010). They 
develop slowly from transformation of endometriotic lesions, hence endometriosis increases 
the risk of developing EC (McCluggage et al., 2002; Nezhat et al., 2008; Pearce et al., 2012). 
Subtype-specific risks are Lynch syndrome as well as high BMI (Olsen et al., 2013; Chui et 
al., 2014). Frequent mutations are those in CTNNB1 (Palacios and Gamallo, 1998), PTEN 
(Obata et al., 1998), KRAS (Cuatrecasas et al., 1997), ARID1A and in the gene coding for the 
catalytic subunit of class I PI3Ks, PIK3CA (Wiegand et al., 2010; Yamamoto et al., 2011; 
Samartzis et al., 2013).  
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1.1.2.3 Clear cell carcinomas 
Clear cell carcinomas (CCC) account for 10-12% of all EOC cases (Köbel et al., 2010). For 
unknown reasons, this subtype has a higher prevalence in Japan, where 15-25% of EOCs are 
CCC (Yoshikawa et al., 2000). Similar to EC, the majority of CCC originate from 
endometriotic lesions (Nezhat et al., 2008). Lynch syndrome and endometriosis increase the 
risk of developing CCC (McCluggage et al., 2002; Pearce et al., 2012; Chui et al., 2014). 
Clear cell tumors are normally p53 wild-type and have low chromosomal instability. 
Mutations in ARID1A and PIK3CA genes are reported in 40-50% of cases (Anglesio et al., 
2011; Yamamoto et al., 2011; Ayhan et al., 2012) and low expression of PTEN is a common 
feature (Hashiguchi et al., 2006). 
1.1.2.4 Mucinous carcinomas 
Mucinous carcinomas (MC) that arises slowly from mucinous borderline lesions accounts for 
3% of EOCs (Köbel et al., 2010). The cell of origin is still unknown. KRAS mutations and 
overexpression of ERBB2 is common (Gemignani et al., 2003; Gilks, 2010; Anglesio et al., 
2013). Subtype-specific risk factors include high BMI and smoking (Collaborative Group on 
Epidemiological Studies of Ovarian Cancer et al., 2012; Olsen et al., 2013). 
1.1.3 Clinical staging and disseminated disease 
Staging of ovarian cancer is done according to FIGO guidelines (Prat and FIGO Committee 
on Gynecologic Oncology, 2014), found in Table 1. The 5-year disease specific survival 
decreases with higher stage, from more than 90% in stage I to less than 20% in stage IV 
(Heintz et al., 2006). Unfortunately, the majority of cases are diagnosed at a late stage (stage 
III or IV), when dissemination is already at hand. The late stage discovery is due to non-
specific symptoms, such as abdominal swelling, urinary and bowel dysfunction, loss of 
appetite, pain and fatigue (Bankhead et al., 2005). Possibly due to slower progression, the 
non-high-grade serous subtypes are detected in early stage (stage I-II) (Köbel et al., 2010) and 
thus have better prognosis, except for CCCs (stage II-IV) that have poor prognosis due to 
chemoresistance (du Bois et al., 2003; Takano et al., 2006; Winter et al., 2007). 
Dissemination is mainly abdominal, either by direct extension from tumors to neighboring 
organs or via exfoliated tumors in peritoneal fluid, ascites (Lengyel, 2010). Malignant ascites, 
frequently associated with the HGSC subtype, cause implantation metastasis in omentum, on 
liver and intestinal surfaces. Invasion in the peritoneum and adhesion to the peritoneal 
mesothelium is facilitated by CD44 (Gardner et al., 1996), β-integrins (Wagner et al., 2011) 
and cancer antigen 125 (CA125) (Gubbels et al., 2006) expressed on the ovarian cancer cell 
surface. Exfoliated tumor cells can reach the pleura through the diaphragm, causing pleural 
effusions. Dissemination through hematologic vasculature is rare while involvement of pelvic 
and/or para-aortic lymph nodes are seen in many cases (Morice et al., 2003). Distant 
metastasis to the lung, liver and bone are primarily seen in patients living with EOC for 
several years.  
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Table 1. 2013 FIGO staging classification for cancer of the ovary, fallopian tube and peritoneum. 
Stage I Tumor confined to ovaries or fallopian tube(s)a 
IA Tumor limited to one ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian 
tube surface; no malignant cells in the ascites or peritoneal washings 
IB Tumor limited to both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian 
tube surface; no malignant cells in the ascites or peritoneal washings 
IC Tumor limited to one or both ovaries or fallopian tube(s) with any of the following: 
   IC1 Surgical spill intraoperatively 
   IC2 Capsule ruptured before surgery or tumor on ovarian or fallopian tube surface 
   IC3 Malignant cells in the ascites or peritoneal washings 
Stage II Tumor involves one or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) 
or primary peritoneal cancerb 
IIA Extension and/or implants on uterus and/or fallopian tubes and/or ovaries 
IIB Extension to other pelvic intra-peritoneal tissues 
Stage III Tumor involves one or both ovaries or fallopian tubes, or primary peritoneal cancer, with 
cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or 
metastasis to the retroperitoneal lymph nodes 
IIIA Positive retroperitoneal lymph nodes and/or metastasis to the retroperitoneal lymph nodes 
   IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven) 
   IIIA1(i) Metastasis ≤ 10 mm in greatest dimension 
   IIIA1(ii) Metastasis > 10 mm in greatest dimension 
   IIIA2 Microscopic extra-pelvic (above the pelvic brim) peritoneal involvement with or without positive 
retroperitoneal lymph nodes 
IIIB Macroscopic peritoneal metastasis beyond the pelvis ≤ 2 cm in greatest dimension, with or 
without metastasis to the retro-peritoneal lymph nodes (includes extension of tumor to capsule of 
liver and spleen without parenchymal involvement of either organ) 
IIIC Macroscopic peritoneal metastasis beyond the pelvis > 2 cm in greatest dimension, with or 
without metastasis to the retro-peritoneal lymph nodes (includes extension of tumor to capsule of 
liver and spleen without parenchymal involvement of either organ) 
Stage IV Distant metastasis excluding peritoneal metastases 
IVA Pleural effusion with positive cytology 
IVB Parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph 
nodes and lymph nodes outside of the abdominal cavity)c 
a It is not possible to have stage I peritoneal cancer 
b Dense adhesions with histologically proven tumor cells justify upgrading apparent stage I tumors to stage II 
c Extra-abdominal metastases include transmural bowel infiltration and umbilical deposit 
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The pathophysiology of malignant ascites is not fully understood but factors that contribute to 
the onset of ascites include lymphatic obstruction by tumor cells, excess vascular 
permeability and other tumor-specific effects such as excess metalloproteinase production 
(Kipps et al., 2013). Ascites is thus a dynamic reservoir containing cytokines, chemokines 
and growth factors that can affect tumor growth and progression through different mechanism 
(Mills et al., 1988; Puiffe et al., 2007; Matte et al., 2012). Even though it is evident that EOC 
creates a highly immunosuppressive environment in the peritoneal cavity (Wertel et al., 
2011), high levels of inflammatory cytokines is found in malignant ascites. Interleukin (IL) 6 
and -8, were found at higher levels in ascites than in serum of EOC patients, and increased 
levels correlated with a poor initial response to paclitaxel treatment (Penson et al., 2000). IL-
6 can promote ovarian tumor growth, migration and invasion (Obata et al., 1997), and 
correlates with chemoresistance (Wang et al., 2010; Cohen et al., 2013). In accordance with 
these findings, high levels of IL-6 in ovarian cancer ascites is associated with shorter 
progression-free survival (Lane et al., 2011). Another factor found in high levels in malignant 
EOC ascites is vascular endothelial growth factor (VEGF) that stimulates the production of 
ascites via increased vascular permeability (Herr et al., 2012). Importantly, VEGF also 
enhances tumor growth and elevated VEGF ascites levels correlates with poor clinical 
outcome (Rudlowski et al., 2006). 
The origin and phenotype of cells in malignant ascites is poorly understood. Tumor cells can 
be present as single cells, loose aggregates or compact spheres, and combinations of the 
different growth-patterns are common (Hudson et al., 2008). Their origin is possibly both 
primary and metastatic tumors. Other non-tumoral cell types, are also present in ascites that 
thus contains a complex heterogeneous mixture of cells (Kipps et al., 2013). Further studies 
are needed to better understand how the cellular and soluble components in malignant ascites 
contribute to advance-stage EOC.  
1.1.4 Treatment 
Standard treatment is debulking surgery, including removal of the ovaries, uterus, fallopian 
tubes, omentum and all visible tumor lesions. Surgery is often followed by chemotherapy, 
typically platinum-based chemotherapy together with paclitaxel5. For selected patients with 
stage IIIC-IV EOC neoadjuvant chemotherapy followed by interval debulking is the preferred 
strategy, especially in the case of comorbidities or extensive non-removable tumor(s). Even 
though Sweden relative other European countries have the highest 5-year age-standardized 
relative survival, 44.1% (De Angelis et al., 2014), there is an urgent need for new treatment 
strategies. One promising agent is bevacizumab, a monoclonal antibody targeting VEGF. 
Recently two randomized phase III trials, GOG 218 and ICON 7, reported significant 
                                                
5 Combinations of either cisplatin or carboplatin with paclitaxel are equally effective in terms of progression-free 
survival and overall survival (du Bois et al., 2003). Carboplatin is less toxic, and is therefore considered a better 
option (Ozols et al., 2003).  
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prolonged progression-free survival (PFS) when bevacizumab was added to standard 
chemotherapy and continued as maintenance therapy (Burger et al., 2011; Perren et al., 
2011). In Sweden, the coming and revised National guideline for epithelial ovarian cancer 
recommends the addition of bevacizumab for the high-risk group with advanced EOC. 
Several ongoing randomized trials evaluate targeted therapies directed towards specific 
subgroups.  
Chemotherapy can also be administrated via intraperitoneal (ip) infusions, which facilitates 
higher local drug concentrations at sites of the disease. Compared to intravenous (iv) 
administration of cisplatin-paclitaxel, ip treatment with the same combination resulted in 
longer median survival but did also cause high toxicity in patients (Armstrong et al., 2006; 
Jaaback et al., 2011). Due to the toxicity and lack of consistent results from trials, ip 
administration is not widely used in Sweden or other European countries.  
Patients usually respond well to initial treatment but approximately 75% of EOC patients will 
relapse into incurable disease within three years (Gonzalez-Martin, 2013). Recurrence 
treatment is based on the time interval from the last course of platinum-based chemotherapy 
until relapse, called platinum-free interval (PFI)6. A PFI of at least six months is considered a 
platinum sensitive recurrence and patients typically respond also to second line platinum-
based treatment. Relapses within six months are considered platinum resistant and additional 
chemotherapy treatment is palliative. Several different agents can be used as mono-treatment 
including metronomic cyclophosphamide, weekly paclitaxel, pegylated liposomal 
doxorubicin, oral etoposide and topotecan but the response rates are low, with 10-15% 
patients responding (Gonzalez-Martin, 2013). Bevacizumab has also been evaluated in 
platinum-sensitive and platinum-resistant recurrent EOC, with positive results. When added 
to carboplatin-gemcitabine bevacizumab significantly prolonged PFS compared to 
carboplatin-gemcitabine alone (Aghajanian et al., 2012). In addition, bevacizumab plus any 
standard treatment for platinum-resistant disease increased the PFS in recurrent platinum-
resistant EOC, recently reported in the AURELIA trial (Pujade-Lauraine et al., 2014).  
The efficacy of chemotherapy is routinely monitored via CA125 levels in serum. Elevated 
CA125 levels is seen in approximately 80% of advanced EOC (Díaz-Padilla et al., 2012) and 
is therefore used as a tool to detect EOC as well as recurrent disease, even though elevated 
levels can be caused also by benign conditions. CA125 levels post-treatment can predict 
treatment outcome, where a rapid decrease implicates a good treatment response while a slow 
decrease or stable CA125 indicates poor outcome with chemoresistance (Gadducci et al., 
2004; Rocconi et al., 2009). Except for CA125, very few EOC biomarkers have been 
established and there is currently no routine marker to distinguish the different subtypes or for 
treatment guidance. 
                                                
6 PFI are clinical guidelines, thus some patients with a PFI < 6 months can still be sensitive for platinum and 
those with a PFI ≥ 6 months can be platinum-resistant. 
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1.2 TUMOR PROGRESSION 
1.2.1 Epithelial-to-mesenchymal transition 
Malignant tumors have the potential to form metastases at distant sites in the body and an 
important step in tumor progression is the process when tumor cells acquire the ability to 
invade nearby tissue. In most epithelial tissues, a thin layer of epithelia is separated from the 
underlying stroma by a basement membrane. Tumors formed in the epithelium are considered 
benign as long as they grow only on the epithelial side, while carcinomas that breach the 
basement membrane have gained motility and invasiveness. To invade, epithelial cells 
change their morphology and gene expression to a morphology and transcriptional program 
characteristic for mesenchymal cells, a process known as epithelial-to-mesenchymal 
transition (EMT). EMT was first discovered as a feature of embryogenesis (Bolender and 
Markwald, 1979) and is, together with the reverse process of mesenchymal-to-epithelial 
transition (MET), crucial for the formation of organs and tissues during embryonic 
development. In the adult body, these transitions normally occur in the process of wound 
healing (Thiery et al., 2009). 
EMT is characterized by the loss of the adherens junction protein epithelial cadherin (E-
cadherin), that is cleaved at the plasma membrane and further degraded (Yilmaz and 
Christofori, 2009). The loss of epithelial junction results in reorganization of the actin 
cytoskeleton and loss of the apical-basal polarity (Huang et al., 2012). E-cadherin is often 
replaced by the mesenchymal adherens junction protein neural cadherin (N-cadherin), 
forming weaker cell-cell bonds that favor cell motility (Thiery, 2002). Downregulation of 
epithelial intermediate filaments, cytokeratins, and upregulation of the mesenchymal 
counterpart vimentin is another event during EMT (Savagner, 2010). Cells often upregulate 
their synthesis and release of matrix metalloproteinase (MMP) 2 and -9 to degrade 
components of basement membrane to further support invasion (Brinckerhoff and Matrisian, 
2002). Transcriptional regulation of EMT includes repression of the gene encoding E-
cadherin, CDH1, via several transcription factors that binds directly at the promoter such as 
Slug, Snail, ZEB1 and -2 or indirectly via Twist (Smit et al., 2009; Fuxe et al., 2010). Slug 
(Guo et al., 2012), Snail and Twist (Mani et al., 2008) have been shown to link EMT to the 
concept of cancer stem cells (See section 1.2.3). 
The tumor-associated stroma actively contributes to tumor progression, and the stromal 
involvement occurs early in epithelial transformation. Tumor cell secretion of growth factors, 
such as VEGF, transforming growth factor-β (TGFβ) and platelet-derived growth factor 
(PDGF) activates the stroma. Activated stromal cells, including fibroblasts, inflammatory 
cells and endothelial cells stimulates tumor proliferation and invasion (Mueller and Fusenig, 
2004). 
Tumor cells that have undergone EMT are thus more mesenchymal and can penetrate the 
basement membrane and enter the vasculature. Metastases formed in distant organs often 
revert to a more epithelial phenotype, via MET (Thiery, 2002), implicating a epithelial-
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mesenchymal plasticity. It is a dynamic process, and it is evident that tumor cells can go 
through a partial EMT (Klymkowsky and Savagner, 2009).There is also a heterogeneity 
within tumors, as demonstrated in colon carcinoma where both primary tumor and its 
corresponding liver metastasis had mixed populations of epithelial-mesenchymal phenotype 
with epithelial characteristics in the center and mesenchymal characteristics at the invasive 
front (Brabletz et al., 2005). 
1.2.2 EMT in EOC 
In the normal ovary, E-cadherin is expressed in CICs while the ovarian surface epithelium 
lacks this expression. It was previously believed that early steps in tumor formation included 
differentiation of OSE to take on characteristics of Müllerian duct-derived epithelia. Such 
differentiation included a MET process since benign adenomas and borderline tumors express 
E-cadherin (Sundfeldt et al., 1997; Davies et al., 1998; Ahmed et al., 2007). However, it is 
now suggested that EOC originates from implantations of fallopian tube epithelium and 
endometrium, both Müllerian duct-derived (Kurman and Shih, 2011). Fallopian tube 
epithelium can also give rise to CICs (Nik et al., 2014) which may explain their altered 
cadherin profile compared to the ovarian surface epithelium. 
Some studies report that E-cadherin expression is reduced in advanced primary tumors 
compared to benign and borderline tumors (Ahmed et al., 2007; Hudson et al., 2008), while 
Davidson et al (2000) showed that E-cadherin is significantly increased in metastatic ovarian 
lesions and ascites compared to the respective primary tumors One can suggest that 
EMT/MET occurs several times during tumor progression, resulting in heterogeneous tumors 
with both epithelial and mesenchymal characteristics. One confounding factor for these type 
of studies is the difficulty to define the primary tumor in advanced-stage disease. In addition, 
the exfoliated cells in malignant ascites may arise from budding of single cells and/or 
multicellular aggregates from primary and/or metastatic tumors into the peritoneal fluid, 
which represent a unique route for dissemination. It is thus possible that the E-cadherin 
expression in such aggregates may be advantageous for overcoming anoikis.  
Further studies are needed to better understand the epithelial-mesenchymal plasticity in EOC 
and how it is related to patient survival. Verhaak et al (2013) studied ovarian HGSC, divided 
into four gene expression signatures; differentiated, immunoreactive, mesenchymal, and 
proliferative, previously described in (Cancer Genome Atlas Research Network, 2011). In 
addition, they also classified survival in good and poor expression profiles and combined the 
different signature-strategies to identify patients with better or worse prognosis. 
Differentiated and immunoreactive signatures had a more favorable prognosis while the 
mesenchymal signature was found in tumors with lower median survival and increased 
platinum resistance (Cancer Genome Atlas Research Network, 2011; Verhaak et al., 2013). 
The tumor-associated stroma and its role in EOC progression is an important topic that has 
gained attention in recent years. Several studies now point out cancer-associated fibroblasts 
(CAFs) as key players in EOC progression. For instance, CAFs are associated with advanced-
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stage disease (Zhang et al., 2011) and promotes EOC growth and metastasis in vivo (Cai et 
al., 2011).  
1.2.3 Tumor-initiating cells 
So-called cancer stem cells (CSCs) are hypothesized to underlie tumor progression as well as 
therapy resistance. The theory claims that a small fraction of tumor cells, CSCs, is 
responsible for initiation of disease and relapses in addition to cause tumor heterogeneity. 
Such subpopulations have been described for several cancer types, including ovarian, but to 
what extent these findings are clinically significant is still not clear. 
CSCs were first described by Lapidot et al (1994), who isolated a highly tumorigenic stem 
cell population in acute myeloid leukemia that could reinitiate the disease in mice. However, 
in the majority of cancers where CSCs have been identified, the origin of this subpopulation 
is not necessarily a normal stem cell, and in most of the cases the origin is unknown (Dean et 
al., 2005). The term tumor-initiating cells (TICs) to describe this subpopulation is 
increasingly used7, in particular as TICs are highly chemoresistant and are believed to initiate 
relapse. Similar to normal stem cells TICs are capable of asymmetric self-renewal, i.e., also 
give rise to more differentiated cancer cells (Alison et al., 2012). The differentiated cells are 
more proliferative and will quickly make up the major tumor burden and respond to treatment 
with chemo- and radiotherapy. An alternative scenario is that TICs develop due to external 
stimuli, such as therapy (illustrated in Figure 3). Regardless of origin, if it is possible to 
identify and isolate a cell population that survives initial treatment, then targeting of these 
cells would most likely improve treatment outcome. 
It is generally agreed that TICs have certain characteristics ex vivo;  
• Increased tumorigenicity when injected in xenograft models, where TICs can establish 
tumors from very few cells compared to non-TICs/mixed populations of same origin. 
 
• Unlimited self-renewal, i.e. that TICs can divide numerous times while still maintaining 
an undifferentiated state.  
 
• Pluripotency in terms of giving rise to new TICs and to differentiated cancer cells. 
 
• Spontaneous formation of spheres in serum-free stem cell medium (SCM) when cultured 
in vitro. 
 
• Resistance to chemo- and radiotherapy. 
 
                                                
7 In addition to CSCs and TICs, this subpopulation of cells are in the literature sometimes referred to as cancer-
initiating cells, therapy-resistant cells or as being ”stem cell-like”.  
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Figure 3. Tumor-initiating cells. TICs may arise from stem cells, partly differentiated cells or tumor cells 
depending on internal and/or external stimuli. Due to pluripotency, TICs give rise to new TICs as well as 
differentiated cells which results in heterogeneous tumors. Differentiated cells are responsive to treatment, while 
TICs survive and are able to form new tumors and cause disease relapse. 
1.2.4 TICs in EOC 
A common strategy to investigate TICs is to sort them out from cell lines or primary samples 
using flow cytometry. No single marker clearly identifies ovarian TICs; instead, 
combinations of markers are used and a variety of TIC profiles are suggested in the literature. 
There is thus a possibility that several different TIC populations exist and cell sorting for only 
one of them fails to cover this diversity. Some markers are based on functional assays, such 
as side population (SP) enrichment to sort out cells expressing ATP-binding cassette (ABC) 
transporters, and the ALDEFLUOR assay that detects aldehyde dehydrogenase family 
(ALDH) enzyme activity (Shah and Landen, 2014). Commonly used markers and suggested 
TIC profiles are discussed below. 
1.2.4.1 Cell surface markers 
Cluster of differentiation (CD) molecules are cell surface markers, and sorting of EOC TICs 
is commonly done based on CD44, CD117, CD133 and CD24. Additional surface proteins 
used are ATP-binding cassette sub-family G member 2 (ABCG2) and epithelial cell adhesion 
molecule (EpCAM). 
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CD44, a hyaluronate receptor involved in cell adhesion, migration and cell-cell interactions is 
frequently used as a marker of both somatic stem cells and TICs (Gardner et al., 1996; 
Garson and Vanderhyden, 2014). In EOC tumors, it is reported that CD44 expression defines 
a highly invasive and chemoresistant TIC population and correlates with shorter PFS in early 
stage disease (Alvero et al., 2009; Steffensen et al., 2011). However, some studies claim that 
CD44+ cells are less aggressive and that the expression can predict a favorable prognosis 
(Sillanpää et al., 2003; Latifi et al., 2012). CD44 is regulated both post- transcriptionally and 
post-translationally but detection of CD44 is performed using antibodies reactive with most 
isoforms (Zöller, 2011), which may explain the inconsistent results.  
CD117, also known as c-Kit, is a type III tyrosine kinase receptor that is activated upon 
binding its ligand stem cell factor (SCF) and initiates signal transduction via several 
pathways, including those of PI3K/Akt and MAPK (Lennartsson and Rönnstrand, 2012). 
Activated CD117 mediates cell survival, proliferation and migration and CD117 is frequently 
mutated and/or upregulated in various types of cancer (Liang et al., 2013). Using EOC tissue 
and ascites in a xenograft model, Luo et al (2011) showed that CD117+ xenograft-derived 
cells had TIC features, including self-renewal, high tumorigenic potential, and 
chemoresistance. 
Prominin-1, or CD133, is a transmembrane glycoprotein with unknown function (Grosse-
Gehling et al., 2013). It is a common marker to define EOC TIC populations and increased 
expression is associated with poor survival (Baba et al., 2009; Curley et al., 2009; Zhang et 
al., 2012a). However, CD133 has been questioned as a TIC marker (Bapat, 2010) mainly due 
to the unknown roles of splice variants and glycosylation forms which together with different 
antibody clones for detection cause inconsistent results (Bidlingmaier et al., 2008; Hermansen 
et al., 2011). 
The cell adhesion molecule CD24 is another questioned marker. Breast cancer TICs are 
defined as CD44+/CD24- (Marsden et al., 2009) while pancreatic TICs are suggested to 
CD44+/CD24+ (Li et al., 2007a), implying a tumor-specific role for CD24. Gao et al (2010) 
showed that in EOC the CD24+ fraction of cells derived from tumor tissue was 
chemoresistant and capable of self-renewal. When injected into immuno-compromised mice, 
the CD24+ cells resulted in tumor formation while the CD24- did not (Gao et al., 2010). 
However, profiles including both CD44+/CD24- (Meng et al., 2012) and CD44+/CD24+/ 
EpCAM+ (Wei et al., 2010; Meirelles et al., 2012) have been suggested to define EOC TIC 
populations. 
ABCG2 is the major ABC transporter protein responsible for efflux of a variety of drugs 
(Zhou et al., 2001; Stacy et al., 2013) as well as the fluorescent dye Hoechst 33342 dye, used 
for SP enrichments. SPs from EOC cell lines and ascites are shown to be highly tumorigenic, 
chemoresistant and capable of self-renewal (Szotek et al., 2006; Hu et al., 2010; Dou et al., 
2011) and ABCG2 is therefore considered to be a TIC marker in EOC. 
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1.2.4.2 Intracellular markers and TIC profiles 
ALDH enzymes are important for detoxification of aldehydes as they catalyze the oxidation 
of aldehydes to carboxylic acids. High expression is reported for both normal stem- and 
progenitor cells and TICs (Marcato et al., 2011). Enzymatic activity can be measured by the 
ALDEFLUOR assay which is frequently used to identify such populations. ALDH1A1 is 
identified as the isoform responsible for stemness features (Marcato et al., 2011). ALDH1A1 
expression and ALDH enzymatic activity were significantly higher in chemotherapy-resistant 
EOC cell lines as compared to their corresponding chemosensitive parental cell lines, and 
ALDHA1A+ cells were more tumorigenic then the ALDH1A1- cells when injected in mice 
(Landen et al., 2010). Interestingly, the authors showed that siRNA-mediated downregulation 
of ALDH1A sensitized resistant cells to chemotherapy both in vitro and in vivo using a 
xenograft model.  
It has been reported that only CD44+ cells express ALDH1A1 (Steffensen et al., 2011). 
Another intracellular marker that is increased in CD44+ cells is myeloid differentiation factor 
88 (MyD88) (Alvero et al., 2009). MyD88 is an important component in Toll-like receptor 4 
(TLR4) signaling pathway and its activation leads further to activation of the transcription 
factor nuclear factor κ-light-chain-enhancer of activated B cells (NFκB) (Akira and Hoshino, 
2003). Paclitaxel is a known activator of TLR4 (Kelly et al., 2006) and treatment led to a 
significant increase of NFκB activity in CD44+cells but not in CD44-cells which instead 
underwent apoptosis, suggesting a role for MyD88 in paclitaxel resistance (Alvero et al., 
2009). 
Two transcription factors important for maintenance of pluripotency in embryonic stem cells, 
Nanog and octamer-binding transcription factor 4 (Oct-4) (Shi and Jin, 2010), are commonly 
used for detection of EOC TICs. Nanog expression correlates with poor clinical outcome in 
serous EOC (Lee et al., 2012) and increased Oct-4 levels are related to high stage and high 
grade tumors (Peng et al., 2010). Of importance, alternative splicing results in several 
isoforms of Oct-4 of which Oct-4A is responsible for pluripotency properties of embryonic 
stem cells (Wang and Dai, 2010). 
Several profiles using combinations of markers, most of them including expression of CD44, 
have been suggested to define TICs in EOC cell lines and tissue, based on tumorigenicity, 
sphere formation in vitro, chemotherapy resistance and, in some cases, poor clinical outcome. 
Profiles include CD44+/CD24- and CD44+/CD24+/EpCAM+ (Wei et al., 2010; Meirelles et 
al., 2012; Meng et al., 2012). Furthermore, CD44+/MyD88+ (Alvero et al., 2009), 
CD44+/CD117+ (Zhang et al., 2008) and ALDH1A1+/CD133+ (Silva et al., 2011; Kryczek et 
al., 2012) profiles have all been reported do define potential TIC populations.  
1.2.4.3 Summary 
Possibly reflecting the heterogeneity of EOC, there is no consensus on one defining EOC TIC 
profile. Most likely, several TIC populations exist and efforts should be made to identify 
subtype-specific TIC profiles. It should also be noted that it is unknown whether the timing, 
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i.e. before or after treatment, for TIC isolation is of importance. If the hypothesis that TICs 
remain after treatment is true, then a larger proportion of TICs would be found directly after 
treatment rather than before. One can speculate that tumors caused by TICs at first have a 
TIC-rich heterogeneous cell population, but due to higher proliferation in the differentiated 
cells the TIC proportion will decrease as the tumor grows. This theory is supported by the 
finding that TIC levels, defined as CD44+ cells, inversely correlated with FIGO stage and 
tumor grade (Steffensen et al., 2011). Although uninvestigated, the same theory should be 
possible to apply to relapsing tumors. 
1.3 ALTERED CELLULAR ENERGETICS 
1.3.1 Warburg…and more! 
Altered cellular energetics of cancer cells was first described in the 1920s by Otto Warburg, 
who discovered that proliferating tumor cells converted the majority of their glucose carbon 
to lactate, even in the presence of oxygen (Warburg et al., 1924). Warburg hypothesized that 
this phenomenon arose from mitochondrial defects causing decreased capacity to convert 
glucose to carbon dioxide. His finding, known as “the Warburg effect”, has been observed in 
numerous cancers which in turn has led to the clinical use of 18F-deoxyglucose positron 
emission tomography (FDG-PET) for detection of tumors. The use of glycolysis instead of 
oxidative phosphorylation (OxPhos) might seem inefficient since aerobic glycolysis of one 
glucose molecule generates only two adenosine 5’-triphosphate (ATP) molecules, while the 
net result from tricarboxylic acid (TCA) cycle and OxPhos is 36 ATP. However, increased 
glucose uptake allows redirection of glycolytic intermediates into various biosynthetic 
pathways to meet the demand for macromolecular synthesis in proliferating cells (Ward and 
Thompson, 2012). 
In contrast to Warburg’s hypothesis, the aerobic glycolysis used by most tumor cells is not 
caused by defective or damaged mitochondria. Although tumors do have the ability to use 
OxPhos to generate ATP from glucose, mitochondrial metabolism is instead partly 
reprogrammed to sustain proliferation. In addition to glucose, cancer cells rely on glutamine 
as their source of carbon. The glutamine is used to provide TCA cycle intermediates that 
further feed to biosynthetic pathways. The use of aerobic glycolysis is thus linked to 
glutamine dependence to maintain the TCA cycle (DeBerardinis et al., 2007, 2008). A 
simplified overview of important metabolic pathways in proliferating tumor cells is shown in 
Figure 4. 
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Figure 4. Metabolic features of malignant cells . Simplified overview of important pathways and biosynthesis 
of amino acids, lipids and nucleotides in proliferating tumor cells. Abbreviations: α-KG, α-ketoglutarate; DHAP, 
dihydroxyacetone phosphate; OAA, oxaloacetate. 
Altered cellular energetics is programmed and regulated by several oncogenes and tumor 
suppressor genes with well-known roles in sustained proliferation. Signaling pathways like 
PI3K/Akt MAPK, and NFκB enhance the transcription of a number of genes that encode 
mediators of glycolysis and glutaminolysis (Levine and Puzio-Kuter, 2010). The metabolome 
of a tumor cell thus mirrors the net result of complex intracellular signaling. Metabolic 
profiling is made possible by metabolomics, an emerging field in cancer research (see section 
1.3.2). 
The identification of tumor-specific metabolic alterations is a promising field for the 
development of new therapeutical strategies. Several important metabolic enzymes have been 
described as possible drug targets and energy modulating substances have been shown to 
efficiently eradicate tumor cells when used as single agents or in combination with standard 
chemotherapeutic drugs (reviewed in Shoshan, 2012 and Zhao et al., 2013).  
Out of many key players in metabolic pathways, the work in this thesis has focused on the 
enzyme hexokinase II (HK-II), the transcriptional co-activator peroxisome proliferator-
activated receptor γ co-activator 1α (PGC1α) and its downstream target mitochondrial 
transcription factor A (TFAM) wherefore they are discussed below. 
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1.3.1.1 Hexokinase II 
The first step of glycolysis, when glucose is phosphorylated, is facilitated by hexokinase 
enzymes. The isoenzyme HK-II is expressed in low levels in normal cells but is frequently 
upregulated in malignant cells (Pedersen et al., 2002; Mathupala et al., 2006). HK-II 
enhances glycolysis via its enzymatic activity, but also through its localization to 
mitochondria where it binds the voltage-dependent anion channel (VDAC). The ATP 
produced in OxPhos is transported out from the mitochondrial via adenine nucleotide 
translocase (ANT) associated with VDAC and supplies mitochondrial HK-II with ATP 
directly from the ATP synthase (Mathupala et al., 2006). The HK-II/VDAC complex has dual 
roles, as it also inhibits the intrinsic apoptosis pathway (Pastorino et al., 2002). Mitochondrial 
binding of HK-II is promoted via PI3K/Akt signaling. Conversely, high levels of the end 
product of HK-IIs enzymatic activity, glucose 6-phosphate (Glucose 6-P), has been reported 
to dissociate the complex (Gottlob et al., 2001).  
 
Figure 5. Dual role of hexokinase II. HK-II binds to VDAC, located in the OMM. Via interaction with ANT, 
in the IMM, ATP produced by the ATP synthase is directly supplied to HK-II that use ATP to convert glucose to 
glucose 6-phospate. In addition, mitochondrial HK-II inhibits apoptosis. Activated Akt promotes the formation 
of this pro-survival complex while high levels of glucose 6-phospate cause dissociation of HK-II. In addition, 
dissociation can also be achieved by 3-BP treatment. Abbreviations: HK-II, hexokinase II; VDAC, voltage-
dependent anion channel; OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane; ANT, 
adenine nucleotide translocase; Glu, glucose; Glu-6-P, glucose 6-phosphate; ATP, adenosine 5’-triphosphate; 
ADP, adenosine 5´-diphosphate; 3-BP, 3-bromopyruvate. 
Mitochondrial bound HK-II is far more often seen in cancer cells than in normal cells 
(Mathupala et al., 2009), wherefore the HK-II/VDAC complex is a potential target for cancer 
therapy. One agent that has been suggested to dissociate HK-II from the mitochondrial 
complex is the lactate/pyruvate analogue 3-bromopyruvate (3-BP) (Chen et al., 2009; Pereira 
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da Silva et al., 2009), reported to have significant anticancer effects in in vivo models of 
hepatocarcinomas but low levels of toxicity in normal cells (Geschwind et al., 2002; Ko et al., 
2004). In 2013, the US Food and Drug Administration (FDA) approved 3-BP for Phase I 
clinical trial in patients with primary and/or metastatic liver cancer8. The use of 3-BP in EOC 
has not been investigated and few studies investigate the role of HK-II in this disease. 
However, a recent study (Suh et al., 2014) shows that high expression of HK-II was 
associated with chemoresistance and decreased PFS in EOC tumors. 
1.3.1.2 PGC1α and TFAM 
The transcriptional coactivator PGC1α is a major coordinator of metabolism and 
mitochondrial function (Austin and St-Pierre, 2012), as well as an important regulator of 
antioxidant defense (Valle et al., 2005; St-Pierre et al., 2006). PGC1α effectors include 
nuclear respiratory factor 1 and 2 (NRF1, NRF2) (Wu et al., 1999), which in turn regulate 
TFAM expression (Virbasius and Scarpulla, 1994). TFAM is needed for transcription of 
mitochondrially encoded OxPhos proteins, but also regulates the structure and copy number 
of mtDNA (Kanki et al., 2004; Kaufman et al., 2007). PGC1α may also directly regulate 
mtDNA transcription (Aquilano et al., 2010). 
Very little is reported on the role of PGC1α in cancer in general. In EOC, lower levels of 
PGC1α have been reported in tumor samples compared to normal ovaries, and PGC1α 
overexpression in vitro led to apoptosis via downregulation of Bcl-2 and upregulation of Bax 
(Zhang et al., 2007a). There are no reported results on the role of PGC1α in chemoresistance. 
However, the role of the PGC1/estrogen-related receptors (ERR) axis is known to regulate 
cancer cell metabolism (Deblois et al., 2013), in turn known to affect treatment response 
(Zhao et al., 2013). 
There are few reports on TFAM and its role in cancer. However, partial loss of mtDNA has 
been shown to increase invasivity and progression in cancer cells originating from lung 
(Amuthan et al., 2002), prostate (Naito et al., 2008; Moro et al., 2009) and breast (Naito et al., 
2008) tissue. As TFAM is a required for normal replication and transcription of mtDNA its 
downregulation might be important for tumor progression. This is in part confirmed in colon 
carcinoma cell lines and tumor biopsies where truncating mutations of TFAM caused 
mtDNA reduction and mitochondrial instability (Guo et al., 2011).  
1.3.2 Metabolomics 
In the era of ”omics” it is now possible to study biological systems on several levels, 
including genomic variances (genomics), gene expression (transcriptomics), protein 
abundance (proteomics) and metabolite concentrations (metabolomics). The metabolic 
composition, i.e. the metabolome, is defined as all low-mass small molecules9 in a given 
                                                
8 Announced at http://presciencelabs.com/prescience-labs-investors/press.php 
9 Molecules <1500 Daltons (Da). 
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system (Halama, 2014). The metabolome of a cell results from its genetic characteristics, 
regulation of gene expression, protein abundance, posttranslational modifications and 
environmental influences, hence the metabolome is a direct readout of the phenotype (Griffin 
and Shockcor, 2004).  
The complete cell metabolome includes all the intracellular metabolites, the endo-
metabolome, as well as all the metabolites surrounding the cell, the exo-metabolome. The 
exo-metabolome, a result from cellular uptake and excretion, can be examined in biofluids 
and are useful for the identification of disease-related biomarkers. However, a more accurate 
reflection of the metabolic state of cells can be found in their intracellular metabolome, 
wherefore cell-based metabolomics is an emerging field (León et al., 2013). 
There are two different strategies to study the metabolome, targeted and untargeted. 
Untargeted metabolomics, also described as global metabolomics, normally consists of 
unbiased analysis of all the possible metabolites in a given biological sample and is usually 
used for hypothesis generation. In contrast, targeted metabolomics focuses on a fraction of 
the metabolites or a metabolic pathway for more detailed studies applied to examine a 
hypothesis (Halama, 2014). Numerous analytical techniques have been developed for these 
studies, most of them based on proton (1H) nuclear magnetic resonance (NMR) or high 
resolution mass spectrometry (HRMS) (Vermeersch and Styczynski, 2013). Typically, 
metabolomic analysis generates huge amounts of data and requires the use of appropriate 
chemometric and statistical techniques to evaluate biological relevant data. 
To answer an biological question using metabolomics, the workflow includes experimental 
design, sample processing, measurement, data processing, data interpretation and result 
validation (León et al., 2013). Knowing how to proceed in each step of the workflow is 
important since any undesired alteration in the metabolome may lead to misleading results. 
Sample processing for intracellular metabolomics of any cell model include culture 
conditions, harvesting technique and metabolite extraction. Unfortunately, no standard 
protocols exist for these procedures which makes it difficult to compare data between 
different laboratories.  
1.3.2.1 Metabolomic studies in EOC 
A number of metabolomic investigations of EOC have been performed, most of them with a 
primary focus to identify diagnostic or prognostic biomarkers, using urine or serum in 
patients with early stage disease (Odunsi et al., 2005; Zhou et al., 2010a; Chen et al., 2011; 
Zhang et al., 2013; Ke et al., 2014). In addition, intracellular metabolic profiling of normal 
ovarian tissue, primary and metastatic tumors (Fong et al., 2011) as well as metabolic patterns 
of borderline versus invasive carcinoma (Denkert et al., 2006) has also been reported, both 
using fresh frozen biopsies from untreated tissues. One recent study investigated the 
proteome and metabolome of cell-free malignant EOC ascites and compared it to cirrhosis-
related ascites (Shender et al., 2014). Taken together, these untargeted studies identify a large 
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number of metabolome differences but their impact on tumor progression and outcome in 
terms of survival needs to be investigated in more detail.  
Recently, targeted metabolomics was used to link metabolic dependence and invasiveness in 
EOC (Yang et al., 2014). Metabolic profiling and metabolite tracing using isotope labeled 
glucose and glutamine revealed increased dependence on glycolysis in low-invasive cell lines 
while highly invasive cell lines were more dependent on glutamine. Furthermore, glutamine 
was found to regulate invasiveness by regulating the activity of signal transducer and 
activator of transcription 3 (STAT3). This study nicely demonstrates how targeted 
metabolomics can be used as a complement to standard in vitro methods, and similar future 
studies will hopefully increase our understanding of metabolic features in EOC and how it 
is linked to disease progression, TICs and chemoresistance. 
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2 AIMS OF THE THESIS 
The overall aim was to study ovarian carcinoma with focus on tumor progression and 
chemoresistance. All studies were performed in EOC cell lines, tumor material and ascites. 
The specific aims of each paper were: 
Paper I: To examine different cell populations in malignant ascites by protein profiling for 
markers of EMT, TICs, metabolism and CAFs.  
Paper II: To investigate long-term effects of cisplatin treatment in terms of EMT and TIC 
features as well as mitochondrial alterations in the treatment surviving cell population, and to 
target these resistant cells. 
Paper III: To study the role of mitochondrial regulation by examining the expression of 
PGC1α and TFAM in a tissue microarray as well as in cell lines, and relate the expression to 
tumor subtypes and treatment response. 
Paper IV: To evaluate protocols for harvesting adherent cells prior to 1H NMR-based 
metabolomics and to detect differences in the polar metabolome of parental versus 
multiresistant cells. 
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3 RESULTS AND DISCUSSION 
3.1 PAPER I 
Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal 
subpopulations in freshly isolated ovarian cancer ascites 
In this study malignant ascites from 22 patients were collected (see Paper I, Table 1 for 
clinicopathological characteristics). The majority was high-grade serous carcinomas and all 
patients were diagnosed with advanced stage of disease (FIGO stages IIIC or IV). Ascites 
were removed from the patients via therapeutic paracentesis whereafter cells were pelleted 
and separated on a discontinuous gradient. The tumor cell fractions were then plated and 
subjected to further analysis. Ascitic samples contained one, two or all three of either single 
cells, loose sheet-like aggregates or spheres, defined as compact spherical aggregates in 
which individual cells could not be discernible. When plated in cell cultures, single cells and 
loose aggregates quickly attached to the surface and formed monolayers, wherefore they were 
entitled M-type cells. In contrast, spheres did not attach to the surface and could be dispersed 
only by passage through a fine-mesh filter. After passaging, these so-called S-type cells 
rapidly formed new spheres, showing that these cells were proliferative.  
M- and S-type cells differed significantly with respect to protein levels of markers of EMT, 
as E-cadherin expression was higher in S-type samples, while vimentin expression was 
associated with M-type (Paper I, Figure 1b). Hence, we concluded the M- and S-type cells 
constitute two separate populations. Expression of CAF markers α-smooth muscle actin (α-
SMA) and platelet-derived growth factor receptor β (PDGFRβ) was also analyzed and results 
demonstrate significantly higher expression levels of α-SMA among M-type cells. In 
addition, all nine samples expressing the CAF marker PDGFRβ were of M-type (Paper I, 
Figure 2). Interestingly, CAFs may originate not only from fibroblasts but also from 
malignant or normal epithelial cells that have undergone EMT (Kalluri and Zeisberg, 2006). 
In line with the findings that EOC CAFs are associated with advanced-stage disease and can 
promote growth and metastasis of EOC in vivo (Cai et al., 2011; Zhang et al., 2011), we 
found that clinical stage IV ascitic samples showed significantly higher expression of α-
SMA, compared with stage IIIC samples (Paper I, Figure 2b).  
High expression of TIC markers and potentially high levels of TICs were demonstrated in 
this study, based on expression of ABCG2, CD44, CD117, EpCAM, Nanog and Oct-4A. 
CD44 was found in nine samples, all M-type, and its expression correlated strongly with that 
of vimentin, and an inverse correlation was found with expression of E-cadherin. M- and S-
type did not differ with regard to ABCG2 and EpCAM, in contrast to CD44 (Paper I, Figure 
3a, Table 2 and 3). CD117 was found in four samples and was not further analyzed. 
When investigating transcription factor Oct-4A, the nuclear isoform of Oct-4 responsible for 
pluripotency properties of embryonic stem cells (Wang and Dai, 2010), we noted a ≈ 90 kDa 
band in addition to the ≈ 40 kDa band corresponding to the 360 aa protein Oct-4A in western 
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blot analyses. Since small ubiquitin-related modifier (SUMO)-1 modification (sumoylation) 
of Oct-4 had previously been found to increase the stability and function of the protein (Wei 
et al., 2007), we sought to investigate if SUMO-Oct-4A could be detected. Using 
immunoprecipitation to pull down SUMO-1 and Oct-4A we could confirm that the ≈ 90 kDa 
band corresponds to SUMO-Oct-4A in EOC cell line SKOV-3 (Paper I, Figure 3b), and 
confirmed the findings in EOC cell lines A2780 and CaOv-4. Sumoylation is a post-
translational modification where small SUMO proteins are covalently bound to proteins to 
modify their function. Similar to ubiquitination, sumoylation is directed by an enzymatic 
cascade involving an activating enzyme complex (E1), a conjugating enzyme (E2) and a 
ligase (E3), resulting in an isopeptide bond between the carboxyl terminus of the SUMO 
protein and specific lysine residue(s) in the target protein (Saitoh and Hinchey, 2000; Wang 
and Dasso, 2009). Interestingly Ubc9, the only E2 enzyme catalyzing SUMO conjugation 
(Zhang et al., 2007b), is upregulated in ovarian carcinoma (Mo et al., 2005) but sumoylated 
Oct-4A has not been investigated. Thus, our study is the first to show presence SUMO-Oct-
4A in EOC. 
SUMO-Oct-4A was observed at varying levels in 24/27 ascitic samples while unmodified 
Oct-4A was found in 17/27 samples and expression levels of both were significantly higher in 
M-type samples compared to S-type (Paper I, Figure 3c and 3d). In contrast, M- and S-type 
cells did not differ with respect to expression levels of the transcription factor Nanog. 
However, we found a strong positive correlation between Nanog and EpCAM in the material, 
independently of sample type (Paper I, Figure 3d, Table 2 and 3). 
We hypothesized that spheres would be more glycolytic as a result from adaptation to internal 
hypoxia and show lover levels of mitochondrial proteins. However, expression of β-F1-ATP 
synthase, reported to be downregulated in cancer cells reflecting low mitochondrial 
respiration and worse prognosis in breast, lung and head-and-neck cancer (López-Ríos et al., 
2007; Willers et al., 2010), and TFAM, which correlates with cellular mitochondrial content 
(Montoya et al., 1997), was similar in M-and S-type samples. Nevertheless, there was a 
positive correlation between β-F1-ATPsynthase and Nanog expression as well as with 
EpCAM, independently of sample type. Hence, we concluded that the Nanoghigh /EpCAMhigh 
population also expresses high levels of β-F1-ATPsynthase. 
Previous studies have suggested that spheres from malignant ascites represent a 
subpopulation of highly malignant cells responsible for disease progression, reviewed in 
(Shield et al., 2009). This assumption is mainly supported by in vitro work on artificial 
spheroids, often on TIC-enriched spheroids cultured in SCM. Our initial hypothesis was 
therefore that spontaneous ascitic spheres would harbor TICs. However, our results show that 
S-type populations were low in TIC markers CD44 and Oct-4A compared to M-type 
populations. Moreover, they did not express CAF markers α-SMA and PDGFRβ and were 
more epithelial, and thus represent a less invasive phenotype than M-type.  
M-type samples could be divided into two subtypes; one that resembled the S-type profile but 
apparently lacked some factor required for sphere formation, and one that was CD44pos, Oct-
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4Ahigh and expressed CAF markers. We also identified Nanoghigh /EpCAMhigh samples that 
represent a TIC subset which may be either M- or S- type and which is separate from the 
CD44pos and Oct-4Ahigh subset observed only in M-type samples (summarized in Figure 6). 
Studies on primary EOC tissues demonstrate that CD44 expression defines a highly invasive 
and chemoresistant TIC population (Zhang et al., 2008; Alvero et al., 2009). We therefore 
suggest that the particular subset of M-type cells expressing CD44 and Oct-4A represents the 
more tumorigenic ascitic cell population. Supporting this, expression of Oct-4 was reported to 
be expressed at higher levels in EOC tumors than in normal ovarian and fallopian tube 
epithelium, and to correlate with advanced FIGO stage and high clinical grading (i.e. low 
differentiated tumors) (Peng et al., 2010; Zhang et al., 2010). 
 
Figure 6. Cell populations in malignant ascites. . Based on our results, we concluded that M- and S-type cells 
in malignant EOC ascites constitute separate cell populations, where the monolayer-forming single M-type cells 
were mesenchymal while the sphere forming S- type cells were epithelial. A subset of M-type samples was 
positive for CD44, were high in Oct-4A and exclusively expressed CAF markers α-SMA and PDGFRβ. An 
additional Nanoghigh /EpCAMhigh subset of TICs was identified and could be found in both M- and S-type 
samples.  
There are contradictory conclusions regarding populations in malignant ascites. In a very 
similar report, published two months after our study, Latifi et al (2012) isolated and 
characterized EOC ascitic cells and compared adherent (AD) and non-adherent (NAD) cells 
for expression of EMT and TIC markers. Results showed that AD cells were higher in 
vimentin, N-cadherin, CD44, MMP-2 and MMP-9, and had low or no expression of E-
cadherin, EpCAM, CA125, Oct-4 and STAT3. Injected into mice10, NAD cells were more 
                                                
10 Cells from three patients. 
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tumorigenic than AD cells. It should be noted, however, that NAD cells were first grown as 
adherent monolayers, which may cause selection and alter their phenotype, before ip 
injection. Interestingly, compared to the original patient ascites, cells from mouse xenograft 
ascites showed decreased levels of EpCAM and CA125 and an increase in CD44 expression. 
In addition, comparison of AD and NAD cells from five chemonaïve (CN) patients and five 
chemoresistant11 (CR) patients showed that EpCAM, Oct-4 and STAT3 levels were increased 
in CR-NAD cells while CD44, MMP9 and Oct-4 expression were increased in CR-AD cells 
(Latifi et al., 2012). CR cells in general were thus higher in expression of TIC markers, in line 
with the potentially high levels of TICs found in our study where all but two patients were in 
relapse with resistant disease. Altogether, this suggests that treatment might select for and/or 
induce expression of TIC markers. 
Nevertheless, the sphere-forming S-type cells in our study are most likely chemoresistant 
since chemotherapeutic drugs do not penetrate such multicellular structures (Fayad et al., 
2009; Tunggal et al., 1999). It is difficult to evaluate the drug response in single cells 
suspensions/monolayers compared to spheres in vitro. One strategy, used by Latifi and 
colleagues, is to mechanically disrupt spheres and analyze the drug response in sphere-
forming cells in a single cell format. This might however change their phenotype and cause 
confusing results. Latifi et al reported that the AD cells were more sensitive to cisplatin, but 
this is possibly a trivial finding considered that they showed more rapid proliferation, 
compared to NAD cells. 
One important factor that may contribute to conflicting results is how to separate tumor cells 
from malignant ascites. We used a gradient separation technique, first described by Bjørge et 
al (Bjørge et al., 2005). When investigating similar preparations of ascites samples the 
proportion of tumor cells were found to be on average 77% (Hjerpe et al., 2014). Latifi and 
colleagues removed red blood cells but did not enrich for tumor cells using gradient 
separation, a protocol that most likely decreases the proportion of tumor cells.  
There also seems to be a difference in the definition of spheres. Unlike Latifi et al, we did not 
classify loose aggregates as spheres since they readily attached to the plastic and formed 
monolayers when grown under standard conditions. However, there is a possibility that the 
aggregates would act differently if plated on low-attachment plates in serum-free medium, the 
culture condition used by Latifi. The fact that they could culture their NAD cell population as 
monolayers after dispersing spheres by pipetting clearly indicates that NAD cells are not 
equivalent to our S-type cell populations. Moreover, the authors emphasized that there was an 
extensive variation in morphology and size of ascitic spheres between different samples and 
also within each patient sample. One in this context interesting study (Strauss et al., 2011) 
identified subpopulations of cells in EOC biopsies and ascites that were in a transitory 
epithelial/mesenchymal (E/M) hybrid stage, with cells that simultaneously expressed 
                                                
11 Defined as recurrent disease within 6-20 month of first line treatment. 
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epithelial and mesenchymal markers. A particular E/M-hybrid that was low in E-cadherin and 
high in CD44 expression, similar to our CD44pos M-type cells, was highly enriched for 
tumor-forming cells in vivo and displayed TIC-associated features. The authors suggest that 
E/M hybrids show high plasticity, are able to differentiate into different lineages under certain 
conditions and show capacity for self-renewal (Strauss et al., 2011).  
To summarize, we show that several populations of potential TICs exist in malignant ascites. 
This may have practical implications for TIC isolation based on cell sorting, since using a 
particular set of markers may result in a particular subset of TICs. The results also imply a 
biological heterogeneity and epithelial-mesenchymal plasticity that may underlie the diversity 
of results found in the literature. We found high levels of sumoylated Oct-4A that most likely 
represent a stabilized form of the protein. In addition, we demonstrate the likely presence of 
CAFs in ascites and show that α-SMA expression was significantly higher in stage IV 
samples compared with stage IIIC.  
3.2 PAPER II 
Repeated cisplatin treatment can lead to a multiresistant tumor cell population with 
stem cell features and sensitivity to 3-bromopyruvate 
The antineoplastic effect of cisplatin is based on its DNA damaging effects, in particular via 
DNA adduct formation, but it can also induce apoptosis via non-nuclear target(s) (Mandic et 
al., 2003). Cisplatin has also been shown to bind mtDNA (Olivero et al., 1995; Podratz et al., 
2011), and since mtDNA mutations have been shown to promote tumor progression 
(Brandon et al., 2006; Lu et al., 2009) we sought to investigate whether long-term exposure to 
cisplatin would cause mitochondrial defects and also if resistance could be associated with 
EMT and/or TIC features. 
To do so, resistant sublines from the EOC cell lines A2780 and SKOV-3 were generated by 
treatment for several passages with increasing concentrations of cisplatin (up to 10µM). 
Surviving cells were allowed to recuperate until near-confluence between treatments. The 
resulting resistant phenotype was confirmed and stable over at least 10 passages without 
cisplatin. A similar protocol for long-term treatment with ethidium bromide (EtBr) that binds 
to mtDNA and destroys it, causes partial loss of mtDNA and has been shown to increase 
invasivity and progression in several cancer types (Amuthan et al., 2002; Naito et al., 2008; 
Moro et al., 2009). We therefore used EtBr to create mtDNA deficient SKOV-3 cells, i.e. 
SKOV-3-ρ0 cells, as a control for damaged mtDNA.  
In the resistant subline of A2780 cells, A2780-R, the 2-fold increase in platinum resistance, 
expressed as half-maximal inhibitory concentration (IC50), could be related to upregulation of 
ABCG2. Since upregulation of this transporter has been reported to decrease the response to 
cisplatin (Herraez et al., 2012) and to be predictive of poor response to platinum-based 
chemotherapy (Kim et al., 2009), these cells were not further investigated. In contrast, the 
resistant subline SKOV-3-R, did not express ABCG2 and the resistance could not be linked 
to increased levels of anti-apoptotic Bcl-2 protein family members, Bcl-2 and Bcl-XL. These 
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cells were highly crossresistant also to the mitotic inhibitor paclitaxel and the antimetabolite 
5-fluorouracil (Paper II, Figure 1a and Table 1).  
Compared to the parental cell line, SKOV-3-R cells presented a more mesenchymal 
morphology. In accordance with having undergone EMT, they showed downregulation of E-
cadherin, upregulation of Snail and Twist and showed increased motility towards a serum 
attractant (Paper II, Figure 2). Expression of EOC TIC markers CD44, CD117 and 
ALDH1A1 were upregulated in SKOV-3-R, whereas levels of Nanog and Oct-4A were 
unaltered (Paper II, Figure 3a and S2). While parental cells did not survive prolonged 
culturing in SCM the resistant cells detached and, within 72 h, formed spheres that could be 
cultured for at least 30 days. Moreover, spheres could be dispersed and re-plated to grow as 
spheres in SCM or as monolayer cells in standard medium, indicating that the cells were 
capable of self-renewal (Paper II, Figure 3d).  
Immunocytochemistry revealed that the proportion of cells positive for E-cadherin decreased 
from approximately 40% in parental SKOV-3 to 10% in SKOV-3-R. In parallel, an increase 
in CD117 expression was seen both as a larger proportion of positive cells and as greater 
expression in a subset of SKOV-3-R cells (Paper II, Figure 3b and 3c). These results 
highlight the complexity of resistance development that can be due to drug-mediated 
selection and/or induction of genetic/phenotypic alterations.  
SKOV-3-ρ0 cells were mtDNA deficient and thus lack the mitochondrial-encoded OxPhos 
proteins. Despite the loss of mtDNA, SKOV-3-ρ0 cells retained a mitochondrial content 
comparable to that of SKOV-3 parental cells, detected as mitochondrial mass (Paper II, 
Figure 1b and 1c). In contrast to multiresistant SKOV-3-R, SKOV-3-ρ0 cells showed no or 
little increase in resistance to platinum-based drugs, no morphological alterations or altered 
expression of EMT markers compared to parental cells (Paper II, Table 1, Figure 2a and 2b). 
CD117 was slightly upregulated in SKOV-3-ρ0 cells, while the other investigated TIC 
markers were unchanged (Paper II, Figure 3a), suggesting that CD117 might be regulated 
via mtDNA status. We noted that SKOV-3-ρ0 cells survived for a prolonged time in SCM 
compared to parental SKOV-3 cells. However, if this was a consequence of CD117 
upregulation or of OxPhos depletion, causing highly glycolytic cells that thrive in the high 
glucose SCM, was not further investigated. Regarding the expected malignant progression in 
ρ0 cells, one can speculate that while partial loss of mtDNA causes progression, the complete 
lack of mtDNA might have low impact or even reverse effects on tumor progression. This is 
supported by the finding that OxPhos Complex III is required for metastatic disease 
(Weinberg et al., 2010). 
Although our initial hypothesis that cisplatin causes damage and/or downregulation of 
mtDNA leading to tumor progression was refuted, we found mitochondrial alterations in 
SKOV-3-R cells. Resistant cells showed a tendency towards increased mtDNA:nDNA ratio 
and significantly increased mitochondrial mass. This was supported by higher levels of the 
mitochondrial proteins VDAC and cytochrome c (Paper II, Figure 1b, 1c and 1d). While 
cytochrome c is required for electron transfer from OxPhos Complex III to Complex IV, 
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VDAC regulates both mitochondrial metabolism and cell death, partly by forming an anti-
apoptotic complex via binding to HK-II (Pastorino et al., 2002; Mathupala et al., 2006). We 
therefore investigated the levels of HK-II, and found that it was slightly upregulated in 
SKOV-3-R cells and, as expected in OxPhos depleted cells, even more so in SKOV-3-ρ0 
(Paper II, Figure 1e).  
While we investigated the effects of long-term exposure to cisplatin in terms of EMT and 
TIC features, similar findings were reported (Latifi et al., 2011). The authors showed that 
cisplatin, at higher concentrations and for shorter time periods than we used12, can induce 
EMT and expression of TIC markers in the EOC cell line OVCA433 as well as in cell 
populations expanded from clinical samples. Our results thus support their findings that 
cisplatin induces classical EMT profiles, including upregulation of Snail and Slug and 
increased motility, and upregulation of TIC markers Oct-4, Nanog, CD44 and CD117. 
However, our data show that lower and indeed clinically more relevant doses of cisplatin can 
lead to EMT and TIC-marker upregulation, and that the resulting multiresistant phenotype is 
stable even in the absence of the drug. SKOV-3-R cells thus represent a steady-state model 
rather than a model for induced responses to treatment. 
Targeting multiresistant TICs is a major treatment challenge (Alison et al., 2012). Since 
CD117 was upregulated in SKOV-3-R we examined the effects of CD117 inhibition on 
resistance. CD117 can be targeted by imatinib mesylate that inhibits CD117 and other 
tyrosine kinase receptors by blocking the active site of the kinase. The IC50 of imatinib 
mesylate was lower in SKOV-3-R than in SKOV-3, but the concentration needed to prevent 
growth was clinically irrelevant (>20µM), since plasma levels likely do not exceed 
approximately 5µM (Druker et al., 2001) (Paper II, Table 2). Subsequently we examined if 
imatinib mesylate at 5 and 10µM could potentiate cisplatin at 2-5µM, but found no effect on 
growth alone or in combination treatment using clinically relevant doses. Nevertheless, the 
increased sensitivity to imatinib mesylate in SKOV-3-R indicated a partial dependence on 
CD117. Latifi and colleagues reported that inhibition of extracellular-signal-regulated kinases 
1/2 (ERK 1/2)13, located downstream of receptor kinases, inhibited the cisplatin-induced 
motility and vimentin levels in OVCA433. Cells treated with 16.5µM cisplatin for 4 + 3 days 
were shown to activate ERK1/2, motility and increased levels of vimentin, responses that 
could be avoided by co-treatment with ERK1/2 inhibitor U0126 (Latifi et al., 2011). We 
could, however, not detect any inhibition of motility or altered morphology in SKOV-3-R 
using the CD117 specific inhibitor ISCK03, that blocks phosphorylation of CD117 and 
consequently downstream phosphorylation of ERK1/2. This might be a result of the different 
protocols used, since cisplatin is well known to activate ERK1/2, and combination treatments 
with ERK inhibitors have been found to potentiate cell death (Brozovic and Osmak, 2007). 
                                                
12 Doses from 3.3 to 33µM cisplatin for 3 days up to a month. 
13 Also known as MAPK1 and MAPK3 
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ERK1/2 activation might be important in acute response to treatment but less so in a stable 
phenotype when the drug is not present. 
Several calorie restriction mimetic phytochemicals have been reported to efficiently target 
TICs, i.e. epigallocatechin gallate (Tang et al., 2012), quercetin (Zhou et al., 2010b) and 
resveratrol (Shankar et al., 2011). We have earlier shown that resveratrol can potentiate 
cisplatin in regrowth experiments (Björklund et al., 2011), and therefore examined the effect 
of these compounds in SKOV-3-R. Of importance when investigating substances that 
modulate energy metabolism, such as resveratrol, is to choose a proper assay to assess drug 
treatment response. Since many of the most frequently used methods to measure cell 
proliferation are based on monotetrazolium salts, e.g. MTT and similar assays that depend on 
reduction via NAD(P)H-dependent oxidoreductase enzymes (Berridge et al., 2005), changes 
in metabolic state of the cells may cause misleading results. We therefore quantified total 
cellular protein using Sulforhodamine B assay (SRB) (Skehan et al., 1990) to determine IC50 
and regrowth capacity following drug treatment. However, using the SRB assay will not 
provide information regarding cell status. Cells might be early apoptotic or senescent but still 
contribute to the read-out via their cellular proteins. As a consequence, it is difficult to 
evaluate short-time responses to treatment but a preferable method when studying longer time 
points. Hence, we treated cells for 72h to estimate IC50 values, and for regrowth experiments 
cells were treated for 48h followed by another 72h in drug-free medium. 
Compared to the parental cells, SKOV-3-R showed increased resistance to all three 
phytochemicals and none of them could potentiate the effect of cisplatin in regrowth 
experiments (Paper II, Table 2 and Figure S4). Due to the upregulation of HK-II in SKOV-
3-R, we examined the effect of 3-BP which exerts its antitumoral action at least in part via 
dissociation of HK-II from mitochondria (Mathupala et al., 2006; Chen et al., 2009). SKOV-
3-R cells were sensitive to 3-BP, and combinations of 3-BP and cisplatin were highly 
antiproliferative in both the parental and resistant cell line, as demonstrated in regrowth 
experiments (Paper II, Table 2 and Figure 4a). 
To further investigate the roles of glucose and HK-II in resistance we used glucose-free 
standard medium supplemented with galactose. In the absence of glucose, cells can generate 
glucose 6-P from galactose via the Leloir pathway, which thus enables evaluation of glucose 
and HK-II function without compromising glycolysis. In addition, it has been shown that 
galactose medium causes dissociation of HK-II from mitochondria, without altering the 
protein expression (Shulga et al., 2010). The growth rates of SKOV-3 and SKOV-3-R cells 
over 72h in galactose medium were essentially unaltered compared to growth rates in 
standard medium containing 11 mM glucose. Cells cultured in galactose medium were 
resistant to 3-BP (Paper II, Table 2), which further supports the role of mitochondrial HK-II 
as a 3-BP target. When sensitivity to cisplatin was evaluated in galactose medium and 
compared with the response in standard medium, SKOV-3 showed a non-significant 
reduction while SKOV-3-R were significantly sensitized to cisplatin (Paper II, Figure 4b), 
indicating that glucose and/or HK-II was required for cisplatin resistance.  
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To recapitulate, we show in this study that long-term repeated cisplatin treatment can lead to 
a multiresistant cell population with stem cell features. Multiresistant cells showed increased 
motility and had undergone EMT. Since resistance could be related to upregulation of VDAC 
and HK-II, forming a anti-apoptotic complex on the outer mitochondrial membrane, resistant 
cells were sensitive to the lactate/ pyruvate analogue 3-BP, which dissociates HK-II from this 
complex. The effect of 3-BP was enhanced by co-treatment using cisplatin in low doses. As 
dissociation of HK-II from mitochondria re-sensitized resistant cells to cisplatin it is 
suggested that resistance, at least in part, depends on HK-II. 
3.3 PAPER III 
Expression of mitochondrial regulators PGC1α and TFAM as putative markers of 
subtype and chemoresistance in epithelial ovarian carcinoma 
Based on the findings that mitochondrial content was higher in the multiresistant cell line 
SKOV-3-R, derived from the EOC cell line SKOV-3 (previously described in Paper II) we 
sought to investigate markers of mitochondrial regulation, PGC1α and TFAM, in these cells. 
In addition, expression of these markers were evaluated and related to tumor subtypes in a 
clinical cohort consisting of 53 primary tumor samples. Clinicopathological features of the 
cohort can be found in Paper III, Table 1. We found no significant difference in median age 
between the subtypes, while significant differences were observed for proliferation marker 
Ki-67, progesterone receptor (PR) and estrogen receptor α (ERα), as well as for the 
distribution across histological stages. 
We found that both mRNA and protein expression of the genes coding for PGC1α and 
TFAM (PPARGC1A and TFAM, respectively) were significantly decreased in SKOV-3-R 
compared to parental SKOV-3 cells (Paper III, Figure 1). In the clinical cohort, 
immunohistochemical staining for PGC1α was cytoplasmic and could be detected in 42/53 
tumors, i.e. in 79% of the samples. Expression varied significantly across all EOC subtypes. 
Of note 8/11 samples negative for PGC1α expression were CCC tumors. We found no 
significant correlation between PGC1α and Ki-67 index, PR, age or histological stage. In 
contrast, there was a significant positive correlation between PGC1α and ERα. Expression of 
TFAM also varied significantly across all EOC subtypes. Positive cytoplasmic staining of 
TFAM was detected in 35 tumors while undetectable in 18 tumors. Of the HGSC tumors, 18 
were positive and three negative, contrasted by CCC with three positive tumors and eleven 
tumors with undetectable levels. There was no significant correlation between TFAM 
expression and PR, age or histological stage. However, similar to PGC1α, there was a 
significant positive correlation between TFAM and ERα expression. In addition, there was a 
significantly higher Ki-67 index in TFAM positive compared to TFAM negative tumors 
(Paper III, Figure 2), possibly reflecting a role for TFAM in highly proliferative cells. Data 
on PGC1α and TFAM expression for all EOC subtypes can be found in Paper III, Table 2. 
As TFAM is regulated in part by PGC1α (Virbasius and Scarpulla, 1994; Finck and Kelly, 
2006; Ventura-Clapier et al., 2008), we investigated the co-expression of these two proteins. 
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EOC tumors were categorized into four groups depending on their expression of PGC1α and 
TFAM; PGC1α-/TFAM-, PGC1α-/TFAM+, PGC1α+/TFAM- and PGC1α+/TFAM+. The 
PGC1α/TFAM expression varied significantly across the EOC subtypes. Co-expression of 
PGC1α/TFAM was found in 33 samples of which 16 were HGSC. Within the HGSC 
subtype, 76% of the tumors were double-positive for PGC1α/TFAM. In contrast, lack of both 
PGC1α and TFAM was observed in nine tumors. Of these nine, all but one were CCC (Paper 
III, Table 3). In addition, there was a significant difference in median Ki-67 index between 
the four groups, where positive TFAM expression was associated with high Ki-67 index 
independently of PGC1α expression. (Paper III, Table 3 and Figure S3). 
In order to investigate if undetectable levels of PGC1α and TFAM correlated with decreased 
mitochondrial content we evaluated the expression of VDAC as a positive control for 
presence of mitochondria. Expression of VDAC was found in all samples and was equal 
across all EOC subtypes (not shown). Since TFAM is important for transcription of mtDNA 
(Kaufman et al., 2007), we also assessed protein expression of the mitochondrial encoded 
protein cytochrome c oxidase subunit 2 (MT-CO2). Of 51 tumors stained for MT-CO2, 47 
were positive and four were negative, whereof three tumors were also TFAM negative. 
However, there was no significant correlation between expression of MT-CO2 and TFAM 
(Paper III, Table S1). In addition, we did not observe any correlation between PGC1α, 
VDAC and MT-CO2 expression wherefore we concluded that the loss of PGC1α and/or 
TFAM did not lead to loss of mitochondrial content.  
To further investigate the decreased TFAM levels found in CCC tumors we assessed 
expression of the Lon protease that regulates TFAM expression via degradation (Matsushima 
et al., 2010; Lu et al., 2013). Cytoplasmic Lon staining was found in 38 tumors and the 
expression was differently distributed across all EOC subtypes. However, there was no 
significant correlation between expression of TFAM and Lon (Paper III, Table S2) 
wherefore we concluded that undetectability of TFAM was not due to Lon-mediated 
degradation. 
Mitochondrial biogenesis has in several reports been linked to expression and localization of 
estrogen and its receptor ERα (Tcherepanova et al., 2000; Klinge, 2008). ERα is expressed at 
different levels in the EOC subtypes, with lowest expression in CCC (Köbel et al., 2008; Sieh 
et al., 2013). This was further confirmed by our data, where 12/14 CCC tumors were ERα 
negative. We also found a positive association between ERα  expression and co-expression of 
PGC1α/TFAM, clearly reflected by the finding that all PGC1α-/TFAM- CCC samples were 
ERα negative. Our results thus demonstrate that the expression of PGC1α and TFAM varied 
significantly between HGSC and CCC, and that co-expression correlated with that of ERα 
and Ki-67 index. 
SKOV-3 cells have been reported to have a 32-basepair deletion in exon 1 of ERα transcript 
and are thus ERα positive but estrogen-insensitive (Hua et al., 1995; Lau et al., 1999). 
However, to further investigate the link between regulation of ERα expression, as such, and 
PGC1α/TFAM, levels of ERα were analyzed on mRNA and protein levels in SKOV-3 
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parental and resistant cells. Multiresistant SKOV-3-R cells showed significantly decreased 
mRNA expression of the ESR1 gene and accordingly decreased ERα protein expression 
compared to parental SKOV-3 cells (Paper III, Figure 4a and 4b). Additionally, since 
accumulation of glycogen characterizes CCC (Ohkawa et al., 1977), we analyzed the 
intracellular glycogen levels in parental and resistant cells. SKOV-3-R were found to 
accumulate significantly higher levels of glycogen compared to parental cells (Paper III, 
Figure 4c). Taken together, the development of resistance in vitro resulted in cells with a 
CCC phenotype, even though they are not of CCC origin.  
CCC, with the characteristic accumulation of intracellular glycogen and poor response to 
chemotherapy, represents a distinct clinicopathological subtype of EOC which requires new 
treatment strategies (Anglesio et al., 2011). Our findings support this notion and we further 
suggest that this phenotype is present not only in chemoresistant primary tumors, but also in 
treated, relapsed tumors, possibly also in non-CCC cases. Interestingly, it has been shown 
that ovarian serous carcinomas altered their morphology and resembled CCC after 
neoadjuvant chemotherapy (McCluggage et al., 2002). Additionally, in a mouse model for 
treatment with trastuzumab, SKOV-3 tumor xenografts were post-treatment found to be 
heterogeneous with large areas of ERα- negative CCC morphology (Faratian et al., 2011). 
Similar findings are presented in our study, as the multiresistant SKOV-3-R cells had 
acquired the CCC phenotype, compared to parental SKOV-3 cells.  
 
Figure 7. Suggested profiles in HGSC and CCC. Ovarian HGSC express PGC1α, TFAM, ERα, have a high 
Ki-67 index and are more responsive to initial platinum-based chemotherapy. A contrary profile is found in 
ovarian CCC, with low/undetectable levels of PGC1α, TFAM, ERα, low Ki-67 index and less response to initial 
chemotherapy. Hematoxylin/eosin stainings of representative HGSC and CCC tumors, magnification 400x, scale 
bar shows 50µM. 
In summary, we identified a profile in CCC tumors consisting of undetectability of 
PGC1α/TFAM, and low levels of ERα and Ki-67 index. This was contrasted by HGSC 
tumors that were characterized by a converse state of PGC1α, TFAM and ERα expression as 
well as a high Ki-67 index (summarized in Figure 7). We propose that the CCC profile, and 
likely also glycogen accumulation, is representative not only of CCC but also 
chemoresistance. Altogether, our data provide insights into the development of 
chemoresistance as well as the diversity of subtypes in EOC and corroborate the need to 
develop subtype specific treatment strategies. 
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3.4 PAPER IV 
Metabolic profiling of epithelial ovarian cancer cell lines: evaluation of harvesting 
protocols for profiling using NMR spectroscopy 
Metabolomics is a promising approach to explore the phenotype of cancer cells since the 
metabolome reflects all small molecules (<1500 Da) in a biological system (Halama, 2014). 
However, well-designed analytical protocols are needed to accurately gain biologically 
relevant data (Teng et al., 2009). Although the use of in vitro cell models is emerging in the 
fields of metabolomics, no current standard for the workflow exists. Metabolomic 
investigations aim to analyze snapshots of ongoing biological processes, hence the harvesting 
method used should immediately stop all enzymatic activity and thereby any changes in 
metabolite levels to fulfill this aim. Leakage of intracellular metabolites is one source of 
error, and has been described for the use of organic solvents when harvesting cells (Sellick et 
al., 2009). Trypsin/EDTA treatment has also been reported to cause metabolite leakage 
compared to a cell scraping technique (Bi et al., 2013). Nevertheless, trypsin/EDTA is 
frequently combined with cell counting to later normalize the data to number of cells 
analyzed. However, alternative normalization strategies have been suggested (Silva et al., 
2013), often in parallel samples to the ones further processed for separation techniques. A 
quick and straightforward harvesting protocol that allows quantification of cell amounts in 
samples used for analysis would be ideal.  
Several harvesting techniques have been reported in the literature of which either harvesting 
with cold organic solvent (often methanol), or by addition of water combined with rapid 
liquid nitrogen freezing are the most common ones (Teng et al., 2009; Bi et al., 2013; León et 
al., 2013). In the present study, we aimed to compare these two methods in adherent ovarian 
cancer cell lines by detection of the polar fraction of the metabolome using 1H NMR 
spectroscopy.  
To further understand how alterations in cellular metabolism are linked to progression and 
chemoresistance, our objective was also to characterize the polar metabolome and detect 
differences between SKOV-3 parental and the multiresistant sub line SKOV-3-R, previously 
described in Paper II and III. We thus used SKOV-3 and SKOV-3-R to evaluate harvesting 
protocols in terms of reproducibility and ability to classify metabolite differences in the 
metabolomes of these cells. Moreover, we identified significant differences in the polar 
metabolome between the two cell lines. 
For each cell line, six biological replicates were harvested in parallel using the two different 
techniques, cold methanol (MeOH) or MilliQ freeze/thaw, generating 24 samples in total. In 
order to study variation during extraction and data acquisition, three samples per protocol and 
cell line were divided in two prior to metabolite extraction, generating additional technical 
replicates. Two pooled quality control (QC) samples, one for the MeOH protocol and one for 
the MilliQ freeze/thaw, were also created by pooling equal volumes of cell extracts. The 
sample set for analysis thus consisted of 38 samples; nine samples per cell line and protocol 
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plus two QC samples. Except for the different harvesting protocols, all additional sample 
handling such as culturing of cells, metabolite extraction and NMR analysis were performed 
in an identical manner. In order to evaluate protein concentration as a normalization strategy, 
an insignificant volume was removed from samples harvested with MilliQ freeze/thaw to 
assess protein concentration using a spectrophotometric assay. Protein concentration could 
not be measured in samples harvested using MeOH due to protein precipitation.  
A low variability in biological replicates is essential for metabolomic studies since it indicates 
high reproducibility, hence increases the probability to detect small differences between 
samples. Here, experimental reproducibility was evaluated by determination of the coefficient 
of variation (CV) for each bin in the NMR spectra. Averaged CVs were lower for MilliQ 
freeze/thaw harvesting compared to MeOH in both cell lines, hence the MilliQ freeze/thaw 
method generated data with lower experimental variability than the MeOH protocol. 
Regardless of harvesting protocol, the parental SKOV-3 cells exhibited considerable lower 
variance than SKOV-3-R, indicating that resistance development increased the heterogeneity 
between biological replicates. 
When comparing the two harvesting techniques, all data were normalized to total NMR 
intensity, and multivariable data analysis was performed using both unsupervised and 
supervised statistical procedures. Unsupervised principle component analysis (PCA) models, 
generated for both cell lines in order to identify differences in metabolic profiles resulting 
from the harvesting method used, indicated minor sample clustering. Thus, we could 
conclude that both harvesting protocols resulted in very similar metabolite profiles in SKOV-
3 and SKOV-3-R. However, S-line plots14 from supervised orthogonal projection to latent 
structures discriminant analysis (OPLS-DA) models revealed minor differences in metabolite 
profiles, based on the choice of harvesting protocol. Levels of creatine and glycine differed 
significantly between harvesting protocols in SKOV-3, while only glycine levels were 
significantly altered in SKOV-3-R (data not shown, for p-values see Paper IV). 
Unsupervised PCA models were also used to evaluate the harvesting techniques. Both MeOH 
and MilliQ freeze/thaw harvesting displayed distinct clustering of SKOV-3 and SKOV-3-R 
according to cell line, indicating that they display different metabolic profiles (Paper IV, 
Figure 1). OPLS-DA was used to evaluate the classification power of models for the different 
harvesting protocols. For each harvesting technique, the sample set was randomly divided 
into a training set consisting of 2/3 of the samples and a test set with the remaining 1/3 
samples. While the training sets were used to create models of the differences between 
SKOV-3 and SKOV-3-R, the test sets were used to evaluate the predictive power of the 
generated models. It was possible to correctly classify all samples, suggesting that both 
protocols can be used to examine differences in the metabolome of SKOV-3 and SKOV-3-R 
(Paper IV, Figure 2). 
                                                
14 S-line plots are used to visualize the OPLS-DA model. It combines the covariance and correlation in a scatter 
plot and can be used for extraction of putative biomarkers. 
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S-line plots from OPLS-DA models revealed differences in the polar metabolome between 
the two cell lines. Major alterations found in SKOV-3-R were decreased levels of creatine, 
glycine, lactate, leucine and myo-inositol and increased levels of glutamate and 
glycerophosphocholine (GPC), compared to the metabolome of SKOV-3. Subsequent t-
testing showed that all the presented alterations, except for lactate, were significant and 
consistent for both harvesting techniques (Paper IV, Figure 3). Similarities, and 
dissimilarities, between two multivariate models can be displayed in a shared and unique 
structure plot (SUS-plot), where similarities are found on the positive diagonal while 
dissimilarities are displayed on the negative diagonal. Here, the similarity in detection of 
metabolite differences between MeOH and MilliQ freeze/thaw harvesting protocols was 
confirmed, since the differences in metabolic profiles between cell lines are found on, or 
close to, the positive diagonal line (Paper IV, Figure 4).  
The differences found here in the polar metabolome between parental SKOV-3 and the 
multiresistant subline SKOV-3-R, that harbors TIC features, are in accordance with recent 
metabolic studies. Glutamate, increased in SKOV-3-R, has been found at higher levels in 
EOC primary tumors, and even more so in omentum metastasis, compared to normal tissue 
(Fong et al., 2011). Decreased levels of glycine in SKOV-3-R are in line with low glycine 
levels detected in lung cancer TICs due to upregulation of glycine decarboxylase (GLDC) 
(Zhang et al., 2012b). Regarding GPC, upregulated in SKOV-3-R, it was reported that high 
levels were associated with worse prognosis in pre- and post-treatment biopsies from breast 
cancer patients (Cao et al., 2012). However, the comparison of the metabolomes of SKOV-3 
and SKOV-3-R was here used to statistically evaluate harvesting techniques, not to prove any 
biological significance. Hence, further investigation of the altered metabolites of SKOV-3-R 
cells is needed to evaluate how these alterations affect the resistant phenotype. 
In this study, two common cell harvesting methods, cold MeOH and MilliQ freeze/thaw, 
were evaluated with focus on reproducibility and model classification power. Since both 
protocols were shown to identify the same alterations between SKOV-3 and SKOV-3-R, we 
conclude that either protocol is appropriate for cell-based metabolomic investigations. 
Nevertheless, MeOH and MilliQ freeze/thaw provides different prospects for further protocol 
refinements. Firstly, the use of an aqueous solvent, instead of an organic one, allows a more 
rigid control of pH during metabolite extraction. Thus, of importance for targeted 
metabolomics, this makes it possible to control which classes of metabolites that are retained 
in the aqueous phase during liquid-liquid extraction and influence the recovery of these 
metabolites. In addition, MilliQ freeze/thaw protocol allows quantification of protein and/or 
DNA using standard techniques in harvested samples useful for normalization of data. Here, 
normalization to protein concentrations was performed in MilliQ freeze/thaw samples to 
investigate the differences between the normalization strategies. Evaluation of protein 
concentration versus total NMR intensity revealed four clearly deviating samples, and a linear 
regression coefficient (R2) for the remaining samples equal to 0.84. The correlation was lower 
than expected, possibly reflecting the low precision of the spectroscopic method used to 
assess protein concentration compare with the high precision NMR. However, observed 
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differences in metabolic profiles of SKOV-3 and SKOV-3-R showed a high degree of 
similarity, regardless of normalization strategy used (data not shown). 
To summarize, we identified significant alterations in the intracellular polar metabolome of 
SKOV-3-R involving decreased levels of creatine, glycine, leucine and myo-inositol and 
increased levels of glutamate and glycerophosphocholine, compared to SKOV-3 cells. 
Furthermore, two harvesting protocols, MeOH and MilliQ freeze/thaw, were statistically 
evaluated and compared. The MilliQ freeze/thaw protocol showed increased reproducibility 
and allows for more options during metabolite extraction and data normalization, thus 
represents a tailored and reliable protocol for metabolic profiling of adherent cells. 
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4 CONCLUSIONS 
 
I. Several populations of potential TICs exist in malignant EOC ascites, highlighting a 
biological heterogeneity and epithelial-mesenchymal plasticity in these tumors. The 
likely presence of CAFs may further contribute to this heterogeneity and expression of 
CAF marker α-SMA were increased in advanced-stage disease. Furthermore, 
transcription factor Oct-4A can be sumoylated in EOC, although the clinical 
significance of this finding needs further evaluation. 
 
II. Long-term repeated cisplatin treatment can select for and/or induce a multiresistant 
cell population with TIC and EMT features. Resistance partly depends on 
upregulation of VDAC and HK-II, forming an anti-apoptotic complex on the 
mitochondria. The lactate/ pyruvate analogue 3-BP, that dissociates this complex, is 
thus a treatment candidate to target these cells.  
 
III. Ovarian CCC and HGSC have different profiles with regard to expression of 
mitochondrial regulators PGC1α and TFAM. The undetectability of these markers in 
CCC is associated with low levels of ERα and decreased Ki-67 index, in clear contrast 
to HGSC that express PGC1α, TFAM and ERα and have high Ki-67 index. The CCC 
profile, and likely also glycogen accumulation, is representative not only of CCC but 
also chemoresistance. These findings provide insights into the development of 
chemoresistance, demonstrate subtype diversity and stress the need for subtype 
specific treatment strategies. 
 
IV. The MilliQ freeze/thaw harvesting protocol is optimal for metabolic profiling of 
adherent cells since it is highly reproducible and allows for optional refinements of 
metabolite extraction and data normalization. Moreover, significant alterations in the 
intracellular polar metabolome of SKOV-3-R cells involves decreased levels of 
creatine, glycine, leucine and myo-inositol and increased levels of glutamate and 
GPC, compared to SKOV-3 cells. These alterations are compatible with reported 
features of TICs but the biological significance of these alterations remains to be 
investigated. 
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5 GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
Firstly, this thesis provides insights into the biology of EOC ascites. We reported that several 
populations of potential TICs and likely also CAFs exist in malignant ascites. Secondly, we 
show that cisplatin can induce and/or select for TIC properties and that chemoresistance can 
be linked to metabolic alterations. We also demonstrate EOC subtype-specific profiles with 
regard to expression of mitochondrial regulators. In addition, we established a tailored and 
reliable protocol for metabolic profiling that can be used to further investigations of such 
mitochondrial/metabolic phenotypes. 
CAF identification (Paper I) was based on commonly used CAF markers α-SMA and 
PDGFRβ. However, we did not evaluate if this expression was found in tumor cells or in a 
contaminating cell population. CAF markers were only expressed in the vimentinpos M-type 
samples. In order to distinguish between tumor cells and fibroblasts one could analyze 
expression of cytokeratin 8 (CK-8) to distinguish tumor cells and fibroblasts, since EOC cells 
have a vimentinpos/CK-8pos profile in contrast to vimentinpos/CK-8neg fibroblasts (personal 
communication; Professor Arne Östman). Furthermore, one might also study the ability of 
cell-free ascites fluid to induce CAF markers in tumor cells and fibroblasts. Indeed, our 
unpublished data revealed that cell-free ascites from samples used in Paper I could induce 
expression of α-SMA in hTERT-immortalized foreskin fibroblasts, but not in the EOC cell 
line SKOV-3. While cell-free ascites has been shown to induce growth, invasion and sphere-
formation in cancer cell lines (Puiffe et al., 2007; Carduner et al., 2014), the effect on 
fibroblasts remains uninvestigated. An ideal cell-model for such studies would be normal or 
immortalized fibroblasts from the ovary, fallopian tube or peritoneum. Functional studies 
may also be performed, for instance to examine if ascites-treated fibroblasts can stimulate 
tumor cell growth. Antibody arrays and/or enzyme-linked immunosorbent assay (ELISA) can 
then be used to correlate levels of selected cytokines, chemokines and growth factors to 
increased CAF marker expression and functional read-outs. Such studies would improve our 
understanding of the pathophysiology of malignant ascites. 
The presence of different populations expressing TIC markers highlights a biological 
heterogeneity and epithelial-mesenchymal plasticity in EOC that warrants further studies. 
Cell sorting for one or two markers will fail to cover this diversity. In general, since TICs are 
suggested as targets for future therapy, research should aim to identify differences between 
TICs and normal stem cells to avoid fatal side effects of such treatment. TICs have been 
suggested to sustain specific metabolic alterations (Scatena, 2012; Pecqueur et al., 2013; Ito 
and Suda, 2014) which might comprise possible therapeutic targets. Our results regarding the 
TIC-like SKOV-3-R cells (Paper II-IV) support the notion of particular alterations, 
including decreased glycine levels. 
In Paper II we showed that cisplatin can select for and/or induce a highly multiresistant cell 
phenotype with EMT and TIC features. Similar findings have been reported not only for 
cisplatin (Latifi et al., 2011) but also paclitaxel (Kajiyama et al., 2007; Craveiro et al., 2013) 
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and for cisplatin-paclitaxel combination treatment (Abubaker et al., 2013). In contrast, there 
are no reports on carboplatin-induced TIC and/or EMT phenotypes in EOC, even though 
sorted TIC populations in general are resistant also to this drug. Nevertheless, carboplatin was 
found to induce self-renewal and pluripotency in hepatocellular carcinoma cells (Hu et al., 
2012). We addressed the question and established carboplatin-resistant EOC sublines using a 
similar protocol as in Paper II with long-term treatment for several passages and increasing 
doses. Similar to SKOV-3-R cells, the carboplatin resistant subline SKOV-3-CaR went 
through EMT and showed increased motility and invasivity (unpublished data). However, in 
the SKOV-3-CaR cells, this was not associated with TICness, suggesting that these two 
events are not always linked and that the underlying differential signaling can be investigated.  
The SKOV-3-CaR cells showed similar mitochondrial alterations as the SKOV-3-R cells, i.e. 
increased mtDNA:nDNA ratio and mitochondrial mass (Paper II and unpublished data), and 
we therefore sought to investigate mitochondrial regulation in these cells. We found that 
expression of PGC1α and TFAM were downregulated in these cells, even though we were 
expecting the opposite. Expressions of these markers were also assessed in an EOC cohort 
(Paper III). We discovered that ovarian CCC and HGSC have different expressional profiles 
of mitochondrial regulators PGC1α and TFAM. Our findings should be validated in a bigger 
cohort and, importantly, further linked to clinical parameters, such as platinum-free interval, 
progression-free survival and overall survival. Other molecular events in the suggested 
profiles can also be evaluated, such as p53 status (commonly mutated in HGSC, wild-type in 
CCC). The CCC profile was further linked to development of resistance in vitro since the 
SKOV-3 sublines acquired a CCC phenotype even though they are not of CCC origin and 
p53 mutated. These cell lines thus represent a good model for further evaluation of PGC1α 
and/or TFAM to define their role in chemoresistance and tumor progression. 
Additional alterations in SKOV-3-R cells were revealed when measuring mitochondrial 
respiration (using Seahorse XF, in collaboration with Professor Pierre Sonveaux, unpublished 
data). Although basal respiration was unchanged, resistant cells had increased reserve 
respiratory capacity, which has been linked to increased ability to withstand oxidative stress 
(Hill et al., 2012). Since PGC1α is an important regulator of antioxidant defense (Valle et al., 
2005; St-Pierre et al., 2006), we hypothesized that reactive oxygen species (ROS) levels 
would be altered in these cells. However, this was not the case. One can speculate that ROS 
regulation is directed in a different manner in resistant cells and interesting candidates to 
study would be NRF1, NRF2 and PGC1β.  
We also addressed if the mitochondrial alterations in resistant sublines, were due to mtDNA 
mutations by sequencing the mitochondrial genomes of two EOC cell lines and their resistant 
sublines. Unpublished results showed no mutations that could explain the phenotype, and we 
concluded that the mitochondrial alterations were not driven by damaged/dysfunctional 
mtDNA. 
Investigation of PI3K/Akt signaling in these cells would also be interesting. Activated Akt 
inhibits the transcriptional activity of PGC1α (Li et al., 2007b) as well as that of glycogen 
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synthase kinase 3β (GSK3β). Inhibition of GSK3β has been linked to induction of EMT (Kao 
et al., 2014) and also increases the activity of glycogen synthase. This might be linked to 
glycogen accumulation and additional alterations related to the CCC profile/chemoresistant 
phenotype. Interestingly, activated Akt also promotes mitochondrial HK-II (Gottlob et al., 
2001), found to be important for resistance in Paper II. 
The role of HK-II in resistance, EMT and TICness remains to be investigated in more detail. 
In Paper II, we show that multiresistant cells sensitive to 3-BP treatment and suggested that 
it was due to targeting of mitochondrial-associated HK-II. However, 3-BP has additional 
targets (Shoshan, 2012b) and other drugs that cause HK-II dissociation, such as the antifungal 
azole derivatives clotrimazole and bifonazole, could be used to further investigate this 
mechanism of resistance. Evaluation of drug response, as well as TICness, would benefit 
from in vivo models in addition to in vitro cell culture procedures.  
HK-II, PGC1α and TFAM are all important for the regulation of cellular energetics. 
Metabolomics will be a useful tool to characterize how these markers affect the metabolome. 
For instance, the glycogen accumulation seen in the CCC phenotype is an interesting 
metabolic alteration that needs further investigation. Parallel samples to the ones used for 1H-
NMR analysis in Paper IV were analyzed using HRMS and evaluation of data is currently 
ongoing. These data provide insights regarding therapy-induced chemoresistance. Additional 
studies using targeted metabolomics will be used for studies on specific metabolic pathways 
in resistant cells as well as in PGC1α siRNA-knockdowns. 
In summary, this thesis provides insights in metabolic alterations of chemoresistance and TIC 
phenotypes in EOC, and further supports the need to develop subtype- and/or phenotype-
specific treatment strategies.  
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